<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7432271\results\search\disease\results.xml">
  <result pre="Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). Abstract The pandemic of coronavirus" exact="disease" post="2019 (COVID-19), with rising numbers of patients worldwide, presents"/>
  <result pre="or vaccines that are proven to be effective against severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2). Several potential candidates or"/>
  <result pre="vaccines that are proven to be effective against severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2). Several potential candidates or repurposed"/>
  <result pre="that are proven to be effective against severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2). Several potential candidates or repurposed drugs"/>
  <result pre="based on our present understanding of SARS-CoV and Middle East" exact="respiratory" post="syndrome coronavirus (MERS-CoV) infections. Finally, we outline clinical trials"/>
  <result pre="on our present understanding of SARS-CoV and Middle East respiratory" exact="syndrome" post="coronavirus (MERS-CoV) infections. Finally, we outline clinical trials currently"/>
  <result pre="response immunotherapy adjunctive therapy 1. Introduction The outbreak of severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has rapidly spread"/>
  <result pre="immunotherapy adjunctive therapy 1. Introduction The outbreak of severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2) infection has rapidly spread worldwide"/>
  <result pre="adjunctive therapy 1. Introduction The outbreak of severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2) infection has rapidly spread worldwide and"/>
  <result pre="The outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)" exact="infection" post="has rapidly spread worldwide and produced unprecedented social and"/>
  <result pre="and can present with symptoms ranging from mild or minimal" exact="respiratory" post="symptoms to acute respiratory distress syndrome (ARDS). During the"/>
  <result pre="with symptoms ranging from mild or minimal respiratory symptoms to" exact="acute" post="respiratory distress syndrome (ARDS). During the last twenty years,"/>
  <result pre="symptoms ranging from mild or minimal respiratory symptoms to acute" exact="respiratory" post="distress syndrome (ARDS). During the last twenty years, coronaviruses"/>
  <result pre="from mild or minimal respiratory symptoms to acute respiratory distress" exact="syndrome" post="(ARDS). During the last twenty years, coronaviruses have caused"/>
  <result pre="years, coronaviruses have caused three epidemics of lethal diseases: severe" exact="acute" post="respiratory syndrome (SARS), Middle East respiratory syndrome (MERS) and"/>
  <result pre="coronaviruses have caused three epidemics of lethal diseases: severe acute" exact="respiratory" post="syndrome (SARS), Middle East respiratory syndrome (MERS) and COVID-19."/>
  <result pre="have caused three epidemics of lethal diseases: severe acute respiratory" exact="syndrome" post="(SARS), Middle East respiratory syndrome (MERS) and COVID-19. SARS-CoV-2"/>
  <result pre="of lethal diseases: severe acute respiratory syndrome (SARS), Middle East" exact="respiratory" post="syndrome (MERS) and COVID-19. SARS-CoV-2 seems to be less"/>
  <result pre="lethal diseases: severe acute respiratory syndrome (SARS), Middle East respiratory" exact="syndrome" post="(MERS) and COVID-19. SARS-CoV-2 seems to be less virulent"/>
  <result pre="from bats to humans is likely to have involved an" exact="intermediate" post="host, as seen for SARS-CoV (palm civets) and MERS-CoV"/>
  <result pre="(dromedary camels). Metagenomic sequencing suggests that Pangolins could be the" exact="intermediate" post="hosts due to the genome similarity of Pangolin-associated coronavirus"/>
  <result pre="reading frame 1 (ORF1) that encode for proteins necessary for" exact="viral" post="replication and generation of the nucleocapsid and spike proteins"/>
  <result pre="on the human ACE2 receptor plays an important role in" exact="viral" post="binding and entry [19]. Cryo-electron microscopy (Cryo-EM) structure analysis"/>
  <result pre="S protein competent for fusion. TMPRSS2 is a serine protease" exact="localized" post="to the plasma membrane that is responsible for proteolysis"/>
  <result pre="has not been identified [23]. The initial step during SARS-CoV-2" exact="infection" post="is the binding of S to its host receptors,"/>
  <result pre="of virus particles by endocytosis and fusion between host and" exact="viral" post="membranes [18]. Following membrane fusion and viral entrance, viral"/>
  <result pre="between host and viral membranes [18]. Following membrane fusion and" exact="viral" post="entrance, viral genomic RNA is released into the cytoplasm"/>
  <result pre="and viral membranes [18]. Following membrane fusion and viral entrance," exact="viral" post="genomic RNA is released into the cytoplasm of infected"/>
  <result pre="strand RNA template is transcribed and forms a complex with" exact="intermediate" post="products for transcription of positive-sense mRNAs including the progeny"/>
  <result pre="RNA polymerases (RdRp) [25]. In the infected cell, newly synthesized" exact="viral" post="genomic RNA, the structural nucleocapsid and envelope glycoproteins are"/>
  <result pre="RNA, the structural nucleocapsid and envelope glycoproteins are assembled into" exact="viral" post="particles in the endoplasmic reticulum (ER) and Golgi apparatus."/>
  <result pre="and Golgi apparatus. In the final step, budding of the" exact="viral" post="particles occur through fusion of the plasma membrane and"/>
  <result pre="symptoms and signs vary from fever and fatigue to severe" exact="respiratory" post="complications and multi-organ failure [26]. Understanding the immunopathogenesis of"/>
  <result pre="types in a variety of human organs, including lung alveolar" exact="epithelial" post="cells and small intestinal epithelial cells, both of which"/>
  <result pre="human organs, including lung alveolar epithelial cells and small intestinal" exact="epithelial" post="cells, both of which are considered potential SARS-CoV-2 routes"/>
  <result pre="SARS-CoV-2 and Virus-Induced Degradation of RNA Sensors Similarly to other" exact="viral" post="infections, the expression of type I interferons (TI IFN),"/>
  <result pre="RNA Sensors Similarly to other viral infections, the expression of" exact="type I" post="interferons (TI IFN), such as interferon (IFN)-Î± and IFN-Î²,"/>
  <result pre="(IFN)-Î± and IFN-Î², determine the innate immune response to SARS-CoV-2" exact="infection" post="[35]. Pathogen associated molecular patterns (PAMPs) such as viral"/>
  <result pre="SARS-CoV-2 infection [35]. Pathogen associated molecular patterns (PAMPs) such as" exact="viral" post="RNA are sensed by pattern recognition receptors (PRRs) on"/>
  <result pre="and the release of pro-inflammatory cytokines (interleukin (IL)-1, IL-6 and" exact="Tumor" post="necrosis factor TNF-Î±), which have been reported to be"/>
  <result pre="which have been reported to be overexpressed significantly in SARS-CoV-2" exact="infection" post="in association with â€œcytokine stormâ€� [37,38]. TI IFNs and"/>
  <result pre="excessive and is one of the major determinants of COVID-19" exact="disease" post="[27]. In addition to TLRs, several other receptors including"/>
  <result pre="proposed to be associated in SARS-CoV-2 immunopathogenesis [40,43]. Like other" exact="viral" post="infections, the SARS-CoV-2 antigens are processed by specific antigen"/>
  <result pre="organs [36]. 6. Regulation of Adaptive Immune Response in SARS-CoV-2" exact="Infection" post="6.1. T-Cell Mediated Immune Responses Against SARS-CoV-2 and Mechanisms"/>
  <result pre="6. Regulation of Adaptive Immune Response in SARS-CoV-2 Infection 6.1." exact="T-Cell" post="Mediated Immune Responses Against SARS-CoV-2 and Mechanisms of Immune"/>
  <result pre="During SARS-CoV infection, the majority (approximately 80%) of inflammatory cells" exact="infiltrating" post="the lungs of affected individuals are CD8+ T cells"/>
  <result pre="CD4+ T cells are more susceptible than CD8+ cells to" exact="infection" post="by MERS-CoV and SARS-CoV [56]. During SARS-CoV-2 infection, a"/>
  <result pre="the production of cytokines (IL-1, LL-6, IL-8, IL-21, TNF-Î±, and" exact="Monocyte" post="chemoattractant protein-1 (MCP-1)) from these cells [30]. The possible"/>
  <result pre="of IL-17 and related altered cytokines are highlighted in SARS-CoV-2" exact="infection" post="[57]. One of the important methods that SARS-CoV-2 may"/>
  <result pre="conveys promise for developing vaccines [58]. 6.2. Humoral Immune and" exact="Antibody" post="Responses to Coronavirus Infection All subtypes of B lymphocytes"/>
  <result pre="vaccines [58]. 6.2. Humoral Immune and Antibody Responses to Coronavirus" exact="Infection" post="All subtypes of B lymphocytes are involved in the"/>
  <result pre="lymphocytes are involved in the humoral immune response against coronavirus" exact="infections" post="[59]. Several antibodies which have been isolated and designated"/>
  <result pre="[64]. Similarly, epitope mapping by Liu et al. identified a" exact="short" post="list of 19 antibodies, equally divided between those targeting"/>
  <result pre="that works tightly with the humoral arm of immunity [66]." exact="Viral" post="proteins can mimic host proteins that regulate the complement"/>
  <result pre="of innate immune cells. Thus, inhibiting C3a and C5a during" exact="infection" post="with MERS-CoV, SARS-CoV or SARS-CoV-2 could be introduced as"/>
  <result pre="SARS-CoV-2 could be introduced as promising targets to treat severe" exact="lung disease" post="[68]. 6.3. Cytokine Responses Across COVID-19; the Significance of"/>
  <result pre="could be introduced as promising targets to treat severe lung" exact="disease" post="[68]. 6.3. Cytokine Responses Across COVID-19; the Significance of"/>
  <result pre="Responses Across COVID-19; the Significance of IL-6 in Cytokine Release" exact="Syndrome" post="(CRS) Although several management strategies are evolving for COVID-19,"/>
  <result pre="(CRS) Although several management strategies are evolving for COVID-19, severe" exact="disease" post="results in the ARDS associated with a cytokine release"/>
  <result pre="disease results in the ARDS associated with a cytokine release" exact="syndrome" post="(CRS). CRS is caused by vast numbers of immune"/>
  <result pre="morbidity of COVID-19 [70]. CRS is not specific to SARS-CoV-2" exact="infection" post="and has been demonstrated for MERS-CoV and SARS-CoV, as"/>
  <result pre="subtypes H5N1 and H7N9 [71]. The hallmarks of CRS are" exact="elevated serum" post="concentrations of pro-inflammatory cytokines including interleukin-6 (IL-6) and C-reactive"/>
  <result pre="demonstrated significantly higher IL-6 levels in people with severe COVID-19" exact="disease" post="than with non-severe disease (mean difference: 38.6 pg/mL, 95%"/>
  <result pre="levels in people with severe COVID-19 disease than with non-severe" exact="disease" post="(mean difference: 38.6 pg/mL, 95% CI: 24.3â€&quot;52.9 pg/mL) and"/>
  <result pre="associated with excess mortality [73]. Binding of SARS-CoV-2 to alveolar" exact="epithelial" post="cells activates the immune system, leading to secretion of"/>
  <result pre="IL-6 is an important pro-inflammatory and multifunctional cytokine involved in" exact="acute" post="inflammation, metabolism, and autoimmune cell differentiation [75]. IL-6 binds"/>
  <result pre="pro-inflammatory and multifunctional cytokine involved in acute inflammation, metabolism, and" exact="autoimmune" post="cell differentiation [75]. IL-6 binds to soluble forms of"/>
  <result pre="of transcription 3 (JAK-STAT3) signaling and inducing CRS [74]. Subsequently," exact="vascular" post="endothelial growth factor (VEGF), MCP-1, IL-8, and more IL-6"/>
  <result pre="reduction of E-cadherin and VEGF overexpression give rise to increased" exact="vascular" post="permeability [77]. IL-6 activates B cells, enhances the expansion"/>
  <result pre="IL-6R [79,80]. It has been approved for the treatment of" exact="rheumatoid arthritis" post="and systemic juvenile idiopathic arthritis and there is increasing"/>
  <result pre="[79,80]. It has been approved for the treatment of rheumatoid" exact="arthritis" post="and systemic juvenile idiopathic arthritis and there is increasing"/>
  <result pre="has been approved for the treatment of rheumatoid arthritis and" exact="systemic" post="juvenile idiopathic arthritis and there is increasing evidence it"/>
  <result pre="been approved for the treatment of rheumatoid arthritis and systemic" exact="juvenile idiopathic arthritis" post="and there is increasing evidence it may be useful"/>
  <result pre="for the treatment of rheumatoid arthritis and systemic juvenile idiopathic" exact="arthritis" post="and there is increasing evidence it may be useful"/>
  <result pre="there is increasing evidence it may be useful for COVID-19" exact="disease" post="[81,82,83]. Clinical analysis of COVID-19 patients admitted to a"/>
  <result pre="in patients admitted to the intensive care unit (ICU) [84]." exact="Tumor" post="necrosis factor-Î± (TNF-Î±) is an inflammatory cytokine secreted by"/>
  <result pre="of innate immune system and is directly correlated with COVID-19" exact="disease" post="severity (R = âˆ’0.322, p &amp;lt; 0.001) [85]. Although"/>
  <result pre="outcomes will help researchers to understand the pathophysiology of SARS-CoV-2" exact="infection" post="and its interactions with underlying chronic diseases. Early clinical"/>
  <result pre="the pathophysiology of SARS-CoV-2 infection and its interactions with underlying" exact="chronic" post="diseases. Early clinical experience suggested that the elderly and"/>
  <result pre="of comorbidities conferred a 3â€&quot;4 fold increased risk of developing" exact="acute" post="respiratory distress syndrome in patients with SARS-CoV [88] and"/>
  <result pre="comorbidities conferred a 3â€&quot;4 fold increased risk of developing acute" exact="respiratory" post="distress syndrome in patients with SARS-CoV [88] and MERS-CoV"/>
  <result pre="a 3â€&quot;4 fold increased risk of developing acute respiratory distress" exact="syndrome" post="in patients with SARS-CoV [88] and MERS-CoV infections [89]."/>
  <result pre="respiratory distress syndrome in patients with SARS-CoV [88] and MERS-CoV" exact="infections" post="[89]. For COVID-19, medical conditions that put people at"/>
  <result pre="medical conditions that put people at increased risk of severe" exact="disease" post="include: uncontrolled diabetes; hypertension; lung, liver, and kidney disease;"/>
  <result pre="that put people at increased risk of severe disease include:" exact="uncontrolled" post="diabetes; hypertension; lung, liver, and kidney disease; cancer; smoking;"/>
  <result pre="of severe disease include: uncontrolled diabetes; hypertension; lung, liver, and" exact="kidney disease;" post="cancer; smoking; solid organ transplant; pregnancy; thalassemia; asthma; neurologic"/>
  <result pre="organ transplant; pregnancy; thalassemia; asthma; neurologic conditions, such as dementia;" exact="pulmonary" post="fibrosis (having damaged or scarred lung tissues); obesity and"/>
  <result pre="as dementia; pulmonary fibrosis (having damaged or scarred lung tissues);" exact="obesity" post="and long term steroid therapy [90,91]. A systematic review"/>
  <result pre="review and meta-analysis of 1576 patients with COVID-19 showed that" exact="hypertension" post="(21.1%) and diabetes (9.7%) were the most prevalent comorbidities,"/>
  <result pre="of 1576 patients with COVID-19 showed that hypertension (21.1%) and" exact="diabetes" post="(9.7%) were the most prevalent comorbidities, followed by cardiovascular"/>
  <result pre="and diabetes (9.7%) were the most prevalent comorbidities, followed by" exact="cardiovascular disease" post="(8.4%) and respiratory disease (1.5%) [92]. This reflects international"/>
  <result pre="diabetes (9.7%) were the most prevalent comorbidities, followed by cardiovascular" exact="disease" post="(8.4%) and respiratory disease (1.5%) [92]. This reflects international"/>
  <result pre="the most prevalent comorbidities, followed by cardiovascular disease (8.4%) and" exact="respiratory" post="disease (1.5%) [92]. This reflects international studies, which show"/>
  <result pre="most prevalent comorbidities, followed by cardiovascular disease (8.4%) and respiratory" exact="disease" post="(1.5%) [92]. This reflects international studies, which show that"/>
  <result pre="show that comorbidities associated with poor outcomes in COVID-19 include" exact="hypertension" post="(20â€&quot;30%), diabetes (10â€&quot;20%), cardiovascular disease (8â€&quot;12%), chronic obstructive pulmonary"/>
  <result pre="comorbidities associated with poor outcomes in COVID-19 include hypertension (20â€&quot;30%)," exact="diabetes" post="(10â€&quot;20%), cardiovascular disease (8â€&quot;12%), chronic obstructive pulmonary disease (COPD)"/>
  <result pre="with poor outcomes in COVID-19 include hypertension (20â€&quot;30%), diabetes (10â€&quot;20%)," exact="cardiovascular disease" post="(8â€&quot;12%), chronic obstructive pulmonary disease (COPD) (1.5â€&quot;7.5%), chronic kidney"/>
  <result pre="poor outcomes in COVID-19 include hypertension (20â€&quot;30%), diabetes (10â€&quot;20%), cardiovascular" exact="disease" post="(8â€&quot;12%), chronic obstructive pulmonary disease (COPD) (1.5â€&quot;7.5%), chronic kidney"/>
  <result pre="in COVID-19 include hypertension (20â€&quot;30%), diabetes (10â€&quot;20%), cardiovascular disease (8â€&quot;12%)," exact="chronic" post="obstructive pulmonary disease (COPD) (1.5â€&quot;7.5%), chronic kidney diseases (1â€&quot;3%),"/>
  <result pre="include hypertension (20â€&quot;30%), diabetes (10â€&quot;20%), cardiovascular disease (8â€&quot;12%), chronic obstructive" exact="pulmonary" post="disease (COPD) (1.5â€&quot;7.5%), chronic kidney diseases (1â€&quot;3%), cerebrovascular disease"/>
  <result pre="hypertension (20â€&quot;30%), diabetes (10â€&quot;20%), cardiovascular disease (8â€&quot;12%), chronic obstructive pulmonary" exact="disease" post="(COPD) (1.5â€&quot;7.5%), chronic kidney diseases (1â€&quot;3%), cerebrovascular disease (1.5â€&quot;3%),"/>
  <result pre="(20â€&quot;30%), diabetes (10â€&quot;20%), cardiovascular disease (8â€&quot;12%), chronic obstructive pulmonary disease" exact="(COPD)" post="(1.5â€&quot;7.5%), chronic kidney diseases (1â€&quot;3%), cerebrovascular disease (1.5â€&quot;3%), co-infection"/>
  <result pre="(10â€&quot;20%), cardiovascular disease (8â€&quot;12%), chronic obstructive pulmonary disease (COPD) (1.5â€&quot;7.5%)," exact="chronic" post="kidney diseases (1â€&quot;3%), cerebrovascular disease (1.5â€&quot;3%), co-infection with human"/>
  <result pre="cardiovascular disease (8â€&quot;12%), chronic obstructive pulmonary disease (COPD) (1.5â€&quot;7.5%), chronic" exact="kidney diseases" post="(1â€&quot;3%), cerebrovascular disease (1.5â€&quot;3%), co-infection with human immunodeficiency virus"/>
  <result pre="chronic obstructive pulmonary disease (COPD) (1.5â€&quot;7.5%), chronic kidney diseases (1â€&quot;3%)," exact="cerebrovascular disease" post="(1.5â€&quot;3%), co-infection with human immunodeficiency virus (HIV) or hepatitis"/>
  <result pre="obstructive pulmonary disease (COPD) (1.5â€&quot;7.5%), chronic kidney diseases (1â€&quot;3%), cerebrovascular" exact="disease" post="(1.5â€&quot;3%), co-infection with human immunodeficiency virus (HIV) or hepatitis"/>
  <result pre="chronic kidney diseases (1â€&quot;3%), cerebrovascular disease (1.5â€&quot;3%), co-infection with human" exact="immunodeficiency" post="virus (HIV) or hepatitis B virus (1â€&quot;2%), malignancy (1â€&quot;3.5%),"/>
  <result pre="cerebrovascular disease (1.5â€&quot;3%), co-infection with human immunodeficiency virus (HIV) or" exact="hepatitis" post="B virus (1â€&quot;2%), malignancy (1â€&quot;3.5%), respiratory illnesses (1.4%), renal"/>
  <result pre="immunodeficiency virus (HIV) or hepatitis B virus (1â€&quot;2%), malignancy (1â€&quot;3.5%)," exact="respiratory" post="illnesses (1.4%), renal disorders (0.5â€&quot;1.5%) and immunodeficiencies (0.01%) [93,94,95,96,97,98]."/>
  <result pre="countries reviewed, as follows: China (hypertension 39.5%), South Korea (cardiovascular" exact="disease" post="25.6%), Italy (hypertension 35.9%), USA (hypertension 38.9%), Mexico, (other"/>
  <result pre="38.9%), Mexico, (other 42.3%), UK (hypertension 27.8%), Iran (diabetes 35.0%);" exact="diabetes" post="was the second most common comorbidity in five of"/>
  <result pre="[93]. Evaluating the mechanisms underlying the associations of severe COVID-19" exact="disease" post="with hypertension, diabetes and respiratory diseases is crucial for"/>
  <result pre="mechanisms underlying the associations of severe COVID-19 disease with hypertension," exact="diabetes" post="and respiratory diseases is crucial for the management of"/>
  <result pre="the associations of severe COVID-19 disease with hypertension, diabetes and" exact="respiratory" post="diseases is crucial for the management of high-risk patients"/>
  <result pre="be considered when managing and treating COVID-19 patients with preexisting" exact="cardiovascular" post="risk factors, especially high blood pressure and diabetes, while"/>
  <result pre="and treating COVID-19 patients with preexisting cardiovascular risk factors, especially" exact="high blood pressure" post="and diabetes, while patients with uncontrolled hypertension should be"/>
  <result pre="factors, especially high blood pressure and diabetes, while patients with" exact="uncontrolled" post="hypertension should be informed about their increased risk and"/>
  <result pre="especially high blood pressure and diabetes, while patients with uncontrolled" exact="hypertension" post="should be informed about their increased risk and advised"/>
  <result pre="measures. 8. Available Treatment Options for COVID-19 An array of" exact="disease" post="modifying drugs have been proposed for the specific treatment"/>
  <result pre="drugs have been proposed for the specific treatment of COVID-19" exact="disease" post="and will be discussed below. The classification of drugs"/>
  <result pre="was originally developed as a treatment for Ebola and Marburg" exact="virus infection" post="and is a promising candidate for treatment of COVID19."/>
  <result pre="originally developed as a treatment for Ebola and Marburg virus" exact="infection" post="and is a promising candidate for treatment of COVID19."/>
  <result pre="premature termination of RNA transcription as it incorporates into nascent" exact="viral" post="RNA chains [99]. Antiviral activity of RDV against coronaviruses"/>
  <result pre="cells has shown that remdesivir at low-micromolar concentrations blocks SARS-CoV-2" exact="infection" post="with high selectivity (half-maximal effective concentration (EC50), 0.77 Î¼M;"/>
  <result pre="of this drug, four clinical trials in severe and mild/moderate" exact="respiratory" post="infections by SARS-CoV-2 in the United States and two"/>
  <result pre="this drug, four clinical trials in severe and mild/moderate respiratory" exact="infections" post="by SARS-CoV-2 in the United States and two in"/>
  <result pre="protease inhibitor antiretroviral agents primarily used for treatment of HIV-1" exact="infection" post="in adults and children over 2 years of age."/>
  <result pre="replication of SARS-CoV and MERS-CoV in vitro [107,108] by inhibiting" exact="viral" post="proteases including 3CLpro or PLpro [108]. Ritonavir is used"/>
  <result pre="(CYP3A4) [109]. A study of six patients with confirmed COVID-19" exact="infection" post="in Korea and China showed a significant decrease in"/>
  <result pre="in Korea and China showed a significant decrease in SARS-CoV-2" exact="viral" post="load and clinical improvement after administration of LPV/r [110,111]."/>
  <result pre="of them improved within 3 days, while two experienced progressive" exact="respiratory" post="failure. [112]. On the other hand, in a retrospective"/>
  <result pre="patients who received LPV/r and were discharged, no differences in" exact="viral" post="shedding duration was noted [113]. Similarly, Cao et al."/>
  <result pre="LPV/r in this study might be attributed to the advanced" exact="pneumonia" post="in treated patients coupled with a lack of knowledge"/>
  <result pre="lack of knowledge about the exact concentrations required to inhibit" exact="viral" post="replication [115]. So far 10 ongoing clinical trials have"/>
  <result pre="that LPV/r has significant drug interactions including the risk of" exact="cardiac arrhythmia" post="due to QT- prolongation [116]. Cao et al. documented"/>
  <result pre="LPV/r has significant drug interactions including the risk of cardiac" exact="arrhythmia" post="due to QT- prolongation [116]. Cao et al. documented"/>
  <result pre="(i.e., anorexia, nausea, abdominal discomfort, or diarrhea) as well as" exact="acute" post="gastritis, hepatic injury risk, pancreatitis, more severe cutaneous eruptions,"/>
  <result pre="well as acute gastritis, hepatic injury risk, pancreatitis, more severe" exact="cutaneous" post="eruptions, and QT prolongation, and the potential for multiple"/>
  <result pre="The use of favipiravir for COVID-19 has been reported from" exact="limited" post="clinical experiences. An open-label study in China compared the"/>
  <result pre="the treatment of COVID-19. Favipiravir was associated with more rapid" exact="viral" post="clearance, better improvement in chest imaging results and less"/>
  <result pre="was associated with more rapid viral clearance, better improvement in" exact="chest" post="imaging results and less adverse effects [120]. Based on"/>
  <result pre="1972 and has been used as a therapeutic agent against" exact="respiratory" post="syncytial virus, Lassa fever virus, influenza A and B"/>
  <result pre="been used as a therapeutic agent against respiratory syncytial virus," exact="Lassa fever" post="virus, influenza A and B and in combination with"/>
  <result pre="influenza A and B and in combination with interferon-Î± for" exact="hepatitis C" post="[126]. Ribavirin has multiple mechanisms of action-including interference with"/>
  <result pre="different cell types of animal or human origin, at considerably" exact="lower" post="concentrations than with either single treatment alone [128]. Similarly,"/>
  <result pre="ribavirin (EC50 of 109.5 ÂµM) are required to reduce the" exact="viral infection" post="and ribavirin is 100 times less potent than remdesivir"/>
  <result pre="(EC50 of 109.5 ÂµM) are required to reduce the viral" exact="infection" post="and ribavirin is 100 times less potent than remdesivir"/>
  <result pre="in SARS trials was associated with serious adverse reactions including" exact="haemolytic anaemia," post="electrolyte disturbances and significant teratogenicity. [88,130,131]. Given its considerable"/>
  <result pre="ribavirin and LPV/r in combination with interferon alpha-1b for SARS-CoV-2" exact="infection" post="[132]. 8.1.5. Arbidol Hydrochloride (Umifenovir) Arbidol (ARB; ethyl-6-bromo-4-[(dimethylamino) methyl]-5-hydroxy-1-methyl-2-[(phenylthio)methyl]-indole-3-carboxylate"/>
  <result pre="in vivo against influenza viruses A, B and C, adenovirus," exact="respiratory" post="syncytial virus, SARS-CoV, parainfluenza type 5, poliovirus, rhinovirus 14,"/>
  <result pre="A, B and C, adenovirus, respiratory syncytial virus, SARS-CoV, parainfluenza" exact="type 5," post="poliovirus, rhinovirus 14, coxsackievirus B5, hantavirus, Chikungunya virus, hepatitis"/>
  <result pre="type 5, poliovirus, rhinovirus 14, coxsackievirus B5, hantavirus, Chikungunya virus," exact="hepatitis" post="B virus (HBV) and hepatitis C virus (HCV) [134]."/>
  <result pre="coxsackievirus B5, hantavirus, Chikungunya virus, hepatitis B virus (HBV) and" exact="hepatitis C" post="virus (HCV) [134]. The anti-viral mechanism of arbidol is"/>
  <result pre="mechanism of arbidol is thought to relate to inhibition of" exact="viral" post="fusion with target cell membranes and with the membranes"/>
  <result pre="major glycoprotein on the surface of the virion, thereby preventing" exact="infection" post="[135]. For SARS-CoV, studies have shown direct antiviral effects"/>
  <result pre="SARS-CoV five times more effectively than arbidol [136]. In China," exact="limited" post="clinical experience with arbidol for COVID-19 treatment has been"/>
  <result pre="treatment for a median duration of 9 days and demonstrated" exact="lower" post="mortality rates (0% (0/36) vs. 16% (5/31)) and higher"/>
  <result pre="a synthetic serine protease inhibitor used for the treatment of" exact="chronic" post="pancreatitis, dystrophic epidermolysis, oral squamous cell carcinoma and exocrine"/>
  <result pre="inhibitor used for the treatment of chronic pancreatitis, dystrophic epidermolysis," exact="oral squamous cell carcinoma" post="and exocrine pancreatic enzyme inhibition [138]. Camostat mesylate was"/>
  <result pre="used for the treatment of chronic pancreatitis, dystrophic epidermolysis, oral" exact="squamous cell carcinoma" post="and exocrine pancreatic enzyme inhibition [138]. Camostat mesylate was"/>
  <result pre="the treatment of chronic pancreatitis, dystrophic epidermolysis, oral squamous cell" exact="carcinoma" post="and exocrine pancreatic enzyme inhibition [138]. Camostat mesylate was"/>
  <result pre="that camostat partially blocked SARS-CoV and human coronavirus NL63 (HCoV-NL63)" exact="infection" post="in HeLa cells expressing the ACE2 receptor and TMPRSS2"/>
  <result pre="[142]. Additionally, the effect of camostat mesylate in blocking SARS-CoV-2" exact="infection" post="of human lung Calu-3 cells has been demonstrated [143]."/>
  <result pre="been approved for the treatment of inflammatory-related diseases such as" exact="pancreatitis" post="[144,145]. Nafamostat is a potent inhibitor of S-mediated membrane"/>
  <result pre="inhibitor of S-mediated membrane fusion of MERS-CoV and blocks MERS-CoV" exact="infection" post="in vitro [22]. The anti MERS-CoV activity of nafamostat"/>
  <result pre="of gabexate mesylate, nafamostat mesylate and camostat mesylate on SARS-CoV-2" exact="infection" post="and demonstrated that nafamostat mesylate inhibited S-mediated entry of"/>
  <result pre="22.50â€‰Î¼M [101]. An advantage of targeting host proteases instead of" exact="viral" post="protein inhibitors is that it avoids treatment failure due"/>
  <result pre="prevent and treat malaria. It has also been tested in" exact="chronic" post="viral diseases and has shown antiviral activity against RNA"/>
  <result pre="and treat malaria. It has also been tested in chronic" exact="viral" post="diseases and has shown antiviral activity against RNA and"/>
  <result pre="influenza A and B viruses, influenza A H5N1 virus, HCV," exact="rabies" post="virus, hepatitis A virus, poliovirus, Chikungunya virus, Lassa virus,"/>
  <result pre="and B viruses, influenza A H5N1 virus, HCV, rabies virus," exact="hepatitis" post="A virus, poliovirus, Chikungunya virus, Lassa virus, Dengue virus,"/>
  <result pre="rabies virus, hepatitis A virus, poliovirus, Chikungunya virus, Lassa virus," exact="Dengue" post="virus, Hendra and Nipah viruses, Crimeanâ€&quot;Congo hemorrhagic fever virus,"/>
  <result pre="Zika virus and Ebola virus, as well as HBV and" exact="herpes" post="simplex virus [147]. Sometimes the antiviral activities of chloroquine"/>
  <result pre="of lysosomes and inhibition of cathepsins. Furthermore, chloroquine interferes with" exact="viral" post="assembly, budding and proteolytic processing of the M protein"/>
  <result pre="evaluated in Vero E6; chloroquine was effective in controlling SARS-CoV-2" exact="infection" post="in vitro with an EC50 at 48 h of"/>
  <result pre="of chloroquine due to the risk of macular retinopathy and" exact="cardiomyopathy" post="[152,153]. Despite the in vitro efficiency of chloroquine, the"/>
  <result pre="base compound, changing the pH of endosomes/lysosomes [155]. There is" exact="limited" post="published evidence supporting the activity of hydroxychloroquine against coronaviruses."/>
  <result pre="open-label trial in France, administration of hydroxychloroquine significantly reduced the" exact="viral" post="load in COVID-19 patients, alone or in combination with"/>
  <result pre="rare adverse effects in patients, including fulminant hepatic failure, serious" exact="cutaneous" post="adverse reactions and ventricular arrhythmias (especially when administrated with"/>
  <result pre="chloroquine for treatment of hospitalized COVID-19 patients can cause serious" exact="heart" post="rhythm problems and other safety issues, including blood and"/>
  <result pre="and lymph system disorders, kidney injuries, liver problems and even" exact="liver failure" post="[163]. Owing to the potential side effectsâ€&quot;namely heart problemsâ€&quot;on"/>
  <result pre="even liver failure [163]. Owing to the potential side effectsâ€&quot;namely" exact="heart" post="problemsâ€&quot;on June 15th the FDA withdrew the emergency use"/>
  <result pre="patients administrated hydroxychloroquine, which found no significant difference in the" exact="primary" post="endpoint of 28-day mortality or hospital stay duration [163,164]."/>
  <result pre="HIV-1, simian virus SV40, dengue virus (DENV), West Nile Virus," exact="Venezuelan equine encephalitis" post="virus (VEEV) and Influenza virus [166]. Ivermectin inhibits the"/>
  <result pre="virus SV40, dengue virus (DENV), West Nile Virus, Venezuelan equine" exact="encephalitis" post="virus (VEEV) and Influenza virus [166]. Ivermectin inhibits the"/>
  <result pre="[167]. Due to the important role of nuclear transport of" exact="viral" post="proteins in the replication cycle as well as inhibition"/>
  <result pre="lines infected with SARS-CoV-2 has shown that ivermectin can reduce" exact="viral" post="RNA up to 5000-fold, equal to a 99.98% reduction"/>
  <result pre="humans [169]. Overall, the possible efficacy of ivermectin against SARS-CoV-2" exact="infection" post="needs data to support it. 9. Immunotherapy Several studies"/>
  <result pre="studies have been undertaken to develop new treatment strategies for" exact="viral" post="infections and the use of immunotherapy is encouraging [170]."/>
  <result pre="have been undertaken to develop new treatment strategies for viral" exact="infections" post="and the use of immunotherapy is encouraging [170]. One"/>
  <result pre="immunity including ready-made antibodies. There are two main categories of" exact="acquired" post="artificial passive immunity against COVID-19: treatment with monoclonal antibodies"/>
  <result pre="recovering from COVID-19 [171]. The antibodies directly bind to the" exact="viral" post="antigen and provide an effective anti-viral response. Several monoclonal"/>
  <result pre="including SARS-CoV and MERS-CoV as well as Ebola virus disease," exact="avian influenza" post="A (H5N1), 2009 H1N1 pandemic influenza A, respiratory syncytial"/>
  <result pre="disease, avian influenza A (H5N1), 2009 H1N1 pandemic influenza A," exact="respiratory" post="syncytial virus, Zika viruses, human cytomegalovirus and rabies have"/>
  <result pre="influenza A, respiratory syncytial virus, Zika viruses, human cytomegalovirus and" exact="rabies" post="have confirmed the presence of neutralizing antibodies in convalescent"/>
  <result pre="plasma was not successful for Ebola [175]. Patients with SARS-CoV-2" exact="infection" post="develop a serum antibody response (IgG) to different epitopes"/>
  <result pre="[177]. A study by Duan et al. [3] of 10" exact="adult" post="patients with severe COVID-19 demonstrated that a single dose"/>
  <result pre="Moreover, clinical and paraclinical symptoms improved within three days and" exact="viral" post="RNA was undetectable in blood seven days after the"/>
  <result pre="patients who were administrated convalescent plasma before day 14 of" exact="disease" post="showed an improved prognosis and a higher discharge rate"/>
  <result pre="convalescent SARS patients to three health care workers with SARS" exact="infection" post="in Taiwan resulted in survival of all three patients,"/>
  <result pre="resulted in survival of all three patients, a decrease in" exact="viral" post="loads to 0 or 1 copy/mL one day after"/>
  <result pre="[194]. As these antibodies are administered intravenously, they can cause" exact="renal failure" post="or thrombosis in MERS patients [195]. For COVID-19, Shi"/>
  <result pre="antibodies are administered intravenously, they can cause renal failure or" exact="thrombosis" post="in MERS patients [195]. For COVID-19, Shi et al."/>
  <result pre="al. reported successful treatment of a confirmed patient with advanced" exact="respiratory" post="failure, shock and persistent diarrhea, using intensive plasma exchange"/>
  <result pre="Similarly, a multicenter retrospective cohort study of 325 critically unwell" exact="adult" post="COVID-19 patients in China who were exposed to IVIG,"/>
  <result pre="prognosis, mortality at 28-days and 60-days was not improved and" exact="total" post="duration of disease was longer [197]. In a retrospective"/>
  <result pre="28-days and 60-days was not improved and total duration of" exact="disease" post="was longer [197]. In a retrospective study of 58"/>
  <result pre="date, several mAbs have been approved by the FDA for" exact="viral" post="infections including SARS-CoV-2 [199]. IL-6 is an attractive target"/>
  <result pre="several mAbs have been approved by the FDA for viral" exact="infections" post="including SARS-CoV-2 [199]. IL-6 is an attractive target for"/>
  <result pre="mAb therapy due to its role in cytokine storm mediated" exact="lung inflammation" post="[200], body temperature regulation and fever. In a study"/>
  <result pre="(recombinant humanized anti IL-6R monoclonal antibody) approved for treatment of" exact="rheumatoid arthritis" post="[202]. It is currently being evaluated in a Phase"/>
  <result pre="humanized anti IL-6R monoclonal antibody) approved for treatment of rheumatoid" exact="arthritis" post="[202]. It is currently being evaluated in a Phase"/>
  <result pre="being evaluated in a Phase 2/3 clinical trial enrolling hospitalized" exact="adult" post="COVID-19 patients, sponsored by Sanofi and Regeneron Pharmaceuticals (NCT04315298)."/>
  <result pre="and Regeneron Pharmaceuticals (NCT04315298). Another inflammatory cytokine involved in COVID-19" exact="disease" post="is TNF-Î±, which can be targeted by mAbs like"/>
  <result pre="and efficacy in COVID-19 treatment in China (ChiCTR2000030089, ChiCTR2000030580). However," exact="upper" post="respiratory tract infections and reactivation of hepatitis B infection"/>
  <result pre="efficacy in COVID-19 treatment in China (ChiCTR2000030089, ChiCTR2000030580). However, upper" exact="respiratory" post="tract infections and reactivation of hepatitis B infection are"/>
  <result pre="COVID-19 treatment in China (ChiCTR2000030089, ChiCTR2000030580). However, upper respiratory tract" exact="infections" post="and reactivation of hepatitis B infection are common and"/>
  <result pre="(ChiCTR2000030089, ChiCTR2000030580). However, upper respiratory tract infections and reactivation of" exact="hepatitis" post="B infection are common and concerning side effects [203]."/>
  <result pre="However, upper respiratory tract infections and reactivation of hepatitis B" exact="infection" post="are common and concerning side effects [203]. Baricitinib is"/>
  <result pre="JAK antagonist monoclonal antibody used routinely for the treatment of" exact="rheumatoid arthritis" post="[204]. Although JAK blockers are considered as potential therapeutic"/>
  <result pre="antagonist monoclonal antibody used routinely for the treatment of rheumatoid" exact="arthritis" post="[204]. Although JAK blockers are considered as potential therapeutic"/>
  <result pre="effects, including lymphocytopenia and neutropenia, and therefore the risk of" exact="viral" post="reactivation [205]. Two other potential mAbs are Leronlimab and"/>
  <result pre="both of which bind specifically to the Câ€&quot;C chemokine receptor" exact="type 5" post="(CCR5). A phase II clinical trial assessing leronlimab in"/>
  <result pre="phase II clinical trial assessing leronlimab in COVID-19 patients with" exact="respiratory" post="complications was registered in April 2020 [206]. Ibalizumab is"/>
  <result pre="signaling rescues exhausted CD8+T cells and restores their activity during" exact="viral" post="infections, but lung toxicity is reported [208]. A clinical"/>
  <result pre="CD8+T cells and restores their activity during viral infections, but" exact="lung toxicity" post="is reported [208]. A clinical trial has been registered"/>
  <result pre="is an IgG1 humanized anti IgE monoclonal antibody that reduces" exact="hypersensitivity" post="to allergens and also decreases late inflammation events, so"/>
  <result pre="from memory B cells from an individual convalescing from SARS-CoV" exact="infection" post="are also capable of neutralizing SARS-CoV-2 [213]. By screening"/>
  <result pre="[213]. By screening hybridomas from immunized mice using pseudotyped vesicular" exact="stomatitis" post="virus, a chimeric mAb called 47D11 was identified which"/>
  <result pre="mAb, which in cell culture was able to block SARS-CoV-2" exact="infection" post="[214]. In another study, four mAbs were isolated from"/>
  <result pre="B38 and H4 were able to bind RBD of the" exact="viral" post="S protein, inhibiting its attachment to ACE2 and reducing"/>
  <result pre="studies have suggested an antiviral function for azithromycin in Ebola" exact="virus infection," post="both in vitro and in mice [216]. Azithromycin (but"/>
  <result pre="telithromycin) can inhibit rhinovirus replication and release in human bronchial" exact="epithelial" post="cells, by inducing expression of interferon and pro-inflammatory cytokines"/>
  <result pre="Huh7), inhibiting late stages of virus replication by enhancing the" exact="type I" post="and III interferon responses [218]. Interestingly, Tran et al."/>
  <result pre="activity of azithromycin against Influenza (H1N1) virus; treatment prior to" exact="infection" post="inhibited virus replication by blocking internalization into host cells,"/>
  <result pre="virus replication by blocking internalization into host cells, without changing" exact="viral" post="attachment [219]. Moreover, intranasal administration of azithromycin to infected"/>
  <result pre="Moreover, intranasal administration of azithromycin to infected mice reduced the" exact="viral" post="load in affected lungs [219]. In a non-randomized clinical"/>
  <result pre="et al. reported that azithromycin co-administered with hydroxychloroquine reduced the" exact="viral" post="load more efficiently than hydroxychloroquine alone [158]. Patients were"/>
  <result pre="are one of the main class of drugs used for" exact="chronic" post="inflammatory diseases and immune disorders. Their anti-inflammatory effects are"/>
  <result pre="main class of drugs used for chronic inflammatory diseases and" exact="immune disorders." post="Their anti-inflammatory effects are attributed to activating the transcription"/>
  <result pre="pro-inflammatory genes through modulation of histone acetylation [220]. For pneumonia," exact="systemic" post="corticosteroids can be used as an adjuvant to antibiotics,"/>
  <result pre="reduce both mortality and morbidity in adults with severe community" exact="acquired" post="pneumonia [221]. Inflammatory responses of host immune cells and"/>
  <result pre="both mortality and morbidity in adults with severe community acquired" exact="pneumonia" post="[221]. Inflammatory responses of host immune cells and the"/>
  <result pre="and morbidity in adults with severe community acquired pneumonia [221]." exact="Inflammatory" post="responses of host immune cells and the resulting cytokine"/>
  <result pre="are two important aspects of the pathogenesis in severe SARS-CoV-2" exact="infection" post="[222]. However, a meta-analysis of previous observational studies revealed"/>
  <result pre="= 2.12) in patients with influenza [223] and can delay" exact="viral" post="clearance in critically ill MERS patients (adjusted hazard ratio"/>
  <result pre="mortality (Risk Ratio RR = 2.11, p-value = 0.019), increased" exact="bacterial infection" post="(RR = 2.08, p &amp;lt; 0.001) and led to"/>
  <result pre="(Risk Ratio RR = 2.11, p-value = 0.019), increased bacterial" exact="infection" post="(RR = 2.08, p &amp;lt; 0.001) and led to"/>
  <result pre="was no significant association between corticosteroid treatment and time to" exact="viral" post="clearance or length of hospitalization [226]. Similarly, Fang et"/>
  <result pre="dose = 237.5 mg/day) had no significant impact on SARS-CoV-2" exact="viral" post="clearance time [227]. Based on these recent results, the"/>
  <result pre="recent results, the World Health Organization (WHO) has not recommended" exact="systemic" post="corticosteroids administration for COVID-19 patients outside of clinical trial"/>
  <result pre="guidelines for COVID-19 patient management released by the Center for" exact="Disease" post="Control and Prevention (CDC), corticosteroid treatment is not recommended"/>
  <result pre="Prevention (CDC), corticosteroid treatment is not recommended in confirmed COVID-19" exact="infections" post="except in cases with exacerbation of chronic obstructive pulmonary"/>
  <result pre="in confirmed COVID-19 infections except in cases with exacerbation of" exact="chronic" post="obstructive pulmonary disease or septic shock [151]. However, recently"/>
  <result pre="COVID-19 infections except in cases with exacerbation of chronic obstructive" exact="pulmonary" post="disease or septic shock [151]. However, recently the randomized"/>
  <result pre="infections except in cases with exacerbation of chronic obstructive pulmonary" exact="disease" post="or septic shock [151]. However, recently the randomized evaluation"/>
  <result pre="in cases with exacerbation of chronic obstructive pulmonary disease or" exact="septic shock" post="[151]. However, recently the randomized evaluation of COVID-19 therapy"/>
  <result pre="not effective for less severe patients who did not required" exact="respiratory" post="support [229,230]. Therefore, reflecting its benefit, the NIH COVID-19"/>
  <result pre="oxygen supplemented COVID-19 patients. However, the possible adverse effects of" exact="secondary" post="infections and hypoglycemia should be considered by the treating"/>
  <result pre="supplemented COVID-19 patients. However, the possible adverse effects of secondary" exact="infections" post="and hypoglycemia should be considered by the treating clinicians"/>
  <result pre="patients. However, the possible adverse effects of secondary infections and" exact="hypoglycemia" post="should be considered by the treating clinicians [2]. 10.3."/>
  <result pre="Oxide (NO) is a free radical with vasodilator properties. In" exact="vascular" post="smooth muscle cells, NO activates soluble guanylate cyclase resulting"/>
  <result pre="is a free radical with vasodilator properties. In vascular smooth" exact="muscle" post="cells, NO activates soluble guanylate cyclase resulting in production"/>
  <result pre="effect (six months after treatment) in ARDS with regard to" exact="pulmonary" post="function [234]. Nitric oxide can inhibit both RNA and"/>
  <result pre="nitric oxide or its derivatives can inhibit palmitoylation of the" exact="viral" post="spike protein, affecting virus binding to its receptor ACE2"/>
  <result pre="concerns raised including small subject numbers, poor study design, the" exact="absence of" post="appropriate controls and end points of unclear utility. Therefore,"/>
  <result pre="The authors declare no conflict of interest. Abbreviations COVID-19 Coronavirus" exact="disease" post="2019 SARS-CoV-2 severe acute respiratory syndrome coronavirus 2 FDA"/>
  <result pre="conflict of interest. Abbreviations COVID-19 Coronavirus disease 2019 SARS-CoV-2 severe" exact="acute" post="respiratory syndrome coronavirus 2 FDA US Food and Drug"/>
  <result pre="of interest. Abbreviations COVID-19 Coronavirus disease 2019 SARS-CoV-2 severe acute" exact="respiratory" post="syndrome coronavirus 2 FDA US Food and Drug Administration"/>
  <result pre="interest. Abbreviations COVID-19 Coronavirus disease 2019 SARS-CoV-2 severe acute respiratory" exact="syndrome" post="coronavirus 2 FDA US Food and Drug Administration MERS-CoV"/>
  <result pre="2 FDA US Food and Drug Administration MERS-CoV Middle East" exact="respiratory" post="syndrome coronavirus ARDS acute respiratory distress syndrome RSCU synonymous"/>
  <result pre="FDA US Food and Drug Administration MERS-CoV Middle East respiratory" exact="syndrome" post="coronavirus ARDS acute respiratory distress syndrome RSCU synonymous codon"/>
  <result pre="and Drug Administration MERS-CoV Middle East respiratory syndrome coronavirus ARDS" exact="acute" post="respiratory distress syndrome RSCU synonymous codon usage NSP non-structural"/>
  <result pre="Drug Administration MERS-CoV Middle East respiratory syndrome coronavirus ARDS acute" exact="respiratory" post="distress syndrome RSCU synonymous codon usage NSP non-structural proteins"/>
  <result pre="MERS-CoV Middle East respiratory syndrome coronavirus ARDS acute respiratory distress" exact="syndrome" post="RSCU synonymous codon usage NSP non-structural proteins ORF open"/>
  <result pre="complex RdRp RNA-dependent RNA polymerases ER endoplasmic reticulum TI IF" exact="type I" post="interferons IFN-Î± interferon-Î± Bcl-xL B-cell lymphoma-extra large PAMPs pathogen"/>
  <result pre="toll-like receptors IRF3 IFN regulatory factor 3 IL interleukin TNF" exact="tumor" post="necrosis factor RLRs RIG-I-like receptors CLRs C-type lectin-like receptors"/>
  <result pre="T lymphocytes CD cluster of differentiation DCs dendritic cells MCP-1" exact="monocyte" post="chemoattractant protein-1 CRS), cytokine release syndrome CRP C-reactive protein"/>
  <result pre="DCs dendritic cells MCP-1 monocyte chemoattractant protein-1 CRS), cytokine release" exact="syndrome" post="CRP C-reactive protein sIL-6R IL-6 receptor JAK-STAT3 Janus kinase-signal"/>
  <result pre="half-maximal effective concentration CC50 half-cytotoxic concentration LPV/r Lopinavir/Ritonavir HIV-1 human" exact="immunodeficiency" post="virus-1 ESICM The European Society of Intensive Care Medicine"/>
  <result pre="The National Institutes of Health FPV Favipiravir ARB Arbidol HCV" exact="hepatitis" post="B virus, hepatitis C virus HA hemagglutinin HCoV-NL63 human"/>
  <result pre="of Health FPV Favipiravir ARB Arbidol HCV hepatitis B virus," exact="hepatitis C" post="virus HA hemagglutinin HCoV-NL63 human coronavirus NL63 DENV dengue"/>
  <result pre="HA hemagglutinin HCoV-NL63 human coronavirus NL63 DENV dengue virus VEEV" exact="Venezuelan equine encephalitis" post="virus IN integrase protein IMP importin mAbs monoclonal antibodies"/>
  <result pre="HCoV-NL63 human coronavirus NL63 DENV dengue virus VEEV Venezuelan equine" exact="encephalitis" post="virus IN integrase protein IMP importin mAbs monoclonal antibodies"/>
  <result pre="IN integrase protein IMP importin mAbs monoclonal antibodies ERGIC ERâ€&quot;Golgi" exact="intermediate" post="compartment IVIG intravenous immunoglobulin PE plasma exchange ICU intensive"/>
  <result pre="WHO World Health Organization PD-1 programmed death-1 CDC left for" exact="disease" post="control and prevention NO nitric oxide cGMP cyclic guanosine"/>
  <result pre="GraafM.LauberC.BestebroerT.M.RajV.S.ZakiA.M.OsterhausA.D.HaagmansB.L.GorbalenyaA.E.SnijderE.J.et al.Genomic Characterization of a Newly Discovered Coronavirus Associated with" exact="Acute" post="Respiratory Distress Syndrome in HumansmBio20123e00473-1210.1128/mBio.00473-1223170002 13.WuA.PengY.HuangB.DingX.WangX.NiuP.MengJ.ZhuZ.ZhangZ.WangJ.et al.Genome Composition and"/>
  <result pre="al.Genomic Characterization of a Newly Discovered Coronavirus Associated with Acute" exact="Respiratory" post="Distress Syndrome in HumansmBio20123e00473-1210.1128/mBio.00473-1223170002 13.WuA.PengY.HuangB.DingX.WangX.NiuP.MengJ.ZhuZ.ZhangZ.WangJ.et al.Genome Composition and Divergence"/>
  <result pre="of a Newly Discovered Coronavirus Associated with Acute Respiratory Distress" exact="Syndrome" post="in HumansmBio20123e00473-1210.1128/mBio.00473-1223170002 13.WuA.PengY.HuangB.DingX.WangX.NiuP.MengJ.ZhuZ.ZhangZ.WangJ.et al.Genome Composition and Divergence of the"/>
  <result pre="Implication for developing subunit vaccineBiochem. Biophys. Res. Commun.200432477378110.1016/j.bbrc.2004.09.10615474494 18.ZhouP.YangX.-L.WangX.-G.HuB.ZhangL.ZhangW.SiH.-R.ZhuY.LiB.HuangC.-L.et al.A" exact="pneumonia" post="outbreak associated with a new coronavirus of probable bat"/>
  <result pre="the Novel Coronavirus from Wuhan: An Analysis Based on Decade-Long" exact="Structural" post="Studies of SARS CoronavirusJ. Virol.20209410.1128/JVI.00127-20 20.WrappD.WangN.CorbettK.GoldsmithJ.A.HsiehC.-L.AbionaO.GrahamB.S.McLellanJ.S.Cryo-EM structure of the"/>
  <result pre="22.YamamotoM.MatsuyamaS.LiX.TakedaM.KawaguchiY.InoueJ.-I.MatsudaZ.Identification of Nafamostat as a Potent Inhibitor of Middle East" exact="Respiratory" post="Syndrome Coronavirus S Protein-Mediated Membrane Fusion Using the Split-Protein-Based"/>
  <result pre="of Nafamostat as a Potent Inhibitor of Middle East Respiratory" exact="Syndrome" post="Coronavirus S Protein-Mediated Membrane Fusion Using the Split-Protein-Based Cell-Cell"/>
  <result pre="Agents Chemother.2016606532653910.1128/AAC.01043-1627550352 23.GuoY.-R.CaoQ.-D.HongZ.TanY.-Y.ChenS.JinH.TanK.S.WangD.Y.YanY.The origin, transmission and clinical therapies on coronavirus" exact="disease" post="2019 (COVID-19) outbreakâ€&quot;An update on the statusMil. Med. Res.202071111010.1186/s40779-020-00240-032169119"/>
  <result pre="outbreakâ€&quot;An update on the statusMil. Med. Res.202071111010.1186/s40779-020-00240-032169119 24.AstutiI.J.D.Research MSC, Reviews." exact="Severe" post="Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): An overview of"/>
  <result pre="update on the statusMil. Med. Res.202071111010.1186/s40779-020-00240-032169119 24.AstutiI.J.D.Research MSC, Reviews. Severe" exact="Acute" post="Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): An overview of viral"/>
  <result pre="on the statusMil. Med. Res.202071111010.1186/s40779-020-00240-032169119 24.AstutiI.J.D.Research MSC, Reviews. Severe Acute" exact="Respiratory" post="Syndrome Coronavirus 2 (SARS-CoV-2): An overview of viral structure"/>
  <result pre="the statusMil. Med. Res.202071111010.1186/s40779-020-00240-032169119 24.AstutiI.J.D.Research MSC, Reviews. Severe Acute Respiratory" exact="Syndrome" post="Coronavirus 2 (SARS-CoV-2): An overview of viral structure and"/>
  <result pre="Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): An overview of" exact="viral" post="structure and host responseDiabetes Metab. Syndr.20201440741210.1016/j.dsx.2020.04.02032335367 25.ChenY.LiuQ.GuoD.Emerging coronaviruses: Genome"/>
  <result pre="Allergy Immunol2020381932105090 28.BourgonjeA.R.AbdulleA.E.TimensW.HillebrandsJ.L.NavisG.J.GordijnS.J.Angiotensin-converting enzyme-2 (ACE2), SARS-CoV-2 and pathophysiology of coronavirus" exact="disease" post="2019 (COVID-19)J. Pathol.202010.1002/path.5471 29.SpiegelM.WeberF.Inhibition of cytokine gene expression and"/>
  <result pre="Immunol.2020202033536210.1038/s41577-020-0353-y 32.PedersenS.F.HoY.-C.SARS-CoV-2: A storm is ragingJ. Clin. Investig.20201302202220510.1172/JCI13764732217834 33.Giamarellos-BourboulisE.NeteaM.G.RovinaN.AkinosoglouK.AntoniadouA.AntonakosN.DamorakiG.GkavogianniT.AdamiM.-E.KatsaounouP.et al.Complex" exact="Immune Dysregulation" post="in COVID-19 Patients with Severe Respiratory FailureCell Host Microbe202027992100010.1016/j.chom.2020.04.00932320677"/>
  <result pre="Clin. Investig.20201302202220510.1172/JCI13764732217834 33.Giamarellos-BourboulisE.NeteaM.G.RovinaN.AkinosoglouK.AntoniadouA.AntonakosN.DamorakiG.GkavogianniT.AdamiM.-E.KatsaounouP.et al.Complex Immune Dysregulation in COVID-19 Patients with" exact="Severe" post="Respiratory FailureCell Host Microbe202027992100010.1016/j.chom.2020.04.00932320677 34.LiuY.DuX.ChenJ.JinY.PengL.WangH.H.LuoM.ChenL.ZhaoY.Neutrophil-to-lymphocyte ratio as an independent"/>
  <result pre="Investig.20201302202220510.1172/JCI13764732217834 33.Giamarellos-BourboulisE.NeteaM.G.RovinaN.AkinosoglouK.AntoniadouA.AntonakosN.DamorakiG.GkavogianniT.AdamiM.-E.KatsaounouP.et al.Complex Immune Dysregulation in COVID-19 Patients with Severe" exact="Respiratory" post="FailureCell Host Microbe202027992100010.1016/j.chom.2020.04.00932320677 34.LiuY.DuX.ChenJ.JinY.PengL.WangH.H.LuoM.ChenL.ZhaoY.Neutrophil-to-lymphocyte ratio as an independent risk"/>
  <result pre="cellsTrends Microbiol.20132138038810.1016/j.tim.2013.06.00123830563 38.ContiP.RonconiG.CaraffaA.GallengaC.RossR.FrydasI.KritasS.Induction of pro-inflammatory cytokines (IL-1 and IL-6) and" exact="lung inflammation" post="by Coronavirus-19 (COVI-19 or SARS-CoV-2): Anti-inflammatory strategiesJ. Biol. Regul."/>
  <result pre="40.PrasadA.Local Immunity Concept in the Context of the Novel Corona" exact="Viral" post="Infection: A ConsiderationAsian J. Immunol.202031625 41.RatajczakM.Z.KuciaM.SARS-CoV-2 infection and overactivation"/>
  <result pre="the Novel Corona Viral Infection: A ConsiderationAsian J. Immunol.202031625 41.RatajczakM.Z.KuciaM.SARS-CoV-2" exact="infection" post="and overactivation of Nlrp3 inflammasome as a trigger of"/>
  <result pre="risk factor for damage of hematopoietic stem cellsLeukemia2020341726172910.1038/s41375-020-0887-932483300 42.LiG.FanY.LaiY.HanT.LiZ.ZhouP.PanP.WangW.HuD.LiuX.et al.Coronavirus" exact="infections" post="and immune responsesJ. Med. Virol.20209242443210.1002/jmv.2568531981224 43.OrtegaJ.T.SerranoM.L.PujolF.H.RangelH.R.Role of changes in"/>
  <result pre="silico analysisEXCLI J.20201941041732210742 44.IshiiK.HasegawaH.NagataN.MizutaniT.MorikawaS.SuzukiT.TaguchiF.TashiroM.TakemoriT.MiyamuraT.et al.Induction of protective immunity against severe" exact="acute" post="respiratory syndrome coronavirus (SARS-CoV) infection using highly attenuated recombinant"/>
  <result pre="analysisEXCLI J.20201941041732210742 44.IshiiK.HasegawaH.NagataN.MizutaniT.MorikawaS.SuzukiT.TaguchiF.TashiroM.TakemoriT.MiyamuraT.et al.Induction of protective immunity against severe acute" exact="respiratory" post="syndrome coronavirus (SARS-CoV) infection using highly attenuated recombinant vaccinia"/>
  <result pre="J.20201941041732210742 44.IshiiK.HasegawaH.NagataN.MizutaniT.MorikawaS.SuzukiT.TaguchiF.TashiroM.TakemoriT.MiyamuraT.et al.Induction of protective immunity against severe acute respiratory" exact="syndrome" post="coronavirus (SARS-CoV) infection using highly attenuated recombinant vaccinia virus"/>
  <result pre="of protective immunity against severe acute respiratory syndrome coronavirus (SARS-CoV)" exact="infection" post="using highly attenuated recombinant vaccinia virus DIsVirology200635136838010.1016/j.virol.2006.03.02016678878 45.BhattacharyaM.SharmaA.R.PatraP.GhoshP.SharmaG.PatraB.C.LeeS.-S.ChakrabortyC.Development of"/>
  <result pre="acute respiratory syndrome coronavirus (SARS-CoV) infection using highly attenuated recombinant" exact="vaccinia" post="virus DIsVirology200635136838010.1016/j.virol.2006.03.02016678878 45.BhattacharyaM.SharmaA.R.PatraP.GhoshP.SharmaG.PatraB.C.LeeS.-S.ChakrabortyC.Development of epitope-based peptide vaccine against novel"/>
  <result pre="al.SARS-CoV Pathogenesis Is Regulated by a STAT1 Dependent but a" exact="Type I," post="II and III Interferon Receptor Independent MechanismPLoS Pathog.20106e100084910.1371/journal.ppat.100084920386712 47.GrifoniA.SidneyJ.ZhangY.ScheuermannR.H.PetersB.SetteA.A"/>
  <result pre="Virol.20203010.1002/rmv.2107 49.KumarS.NyoduR.MauryaV.K.SaxenaS.K.SaxenaS.K.Host Immune Response and Immunobiology of Human SARS-CoV-2 InfectionCoronavirus" exact="Disease" post="2019 (COVID-19)Springer Science and Business Media LLCBerlin/Heidelberg, Germany20204353 50.NeteaM.G.Giamarellos-BourboulisE.J.DomÃ­nguez-AndrÃ©sJ.CurtisN.Van"/>
  <result pre="Germany20204353 50.NeteaM.G.Giamarellos-BourboulisE.J.DomÃ­nguez-AndrÃ©sJ.CurtisN.Van CrevelR.Van De VeerdonkF.L.BontenM.Trained Immunity: A Tool for Reducing" exact="Susceptibility to" post="and the Severity of SARS-CoV-2 InfectionCell202018196997710.1016/j.cell.2020.04.04232437659 51.GanjiA.FarahaniI.KhansarinejadB.GhazaviA.MosayebiG.Increased expression of"/>
  <result pre="VeerdonkF.L.BontenM.Trained Immunity: A Tool for Reducing Susceptibility to and the" exact="Severity of" post="SARS-CoV-2 InfectionCell202018196997710.1016/j.cell.2020.04.04232437659 51.GanjiA.FarahaniI.KhansarinejadB.GhazaviA.MosayebiG.Increased expression of CD8 marker on T-cells"/>
  <result pre="of SARS-CoV-2 infectionâ€&quot;a review of immune changes in patients with" exact="viral" post="pneumoniaEmerg. Microbes Infect.2020972773210.1080/22221751.2020.174619932196410 57.CafarottiS.Severe Acute Respiratory Syndromeâ€&quot;Coronavirus-2 Infection and"/>
  <result pre="immune changes in patients with viral pneumoniaEmerg. Microbes Infect.2020972773210.1080/22221751.2020.174619932196410 57.CafarottiS.Severe" exact="Acute" post="Respiratory Syndromeâ€&quot;Coronavirus-2 Infection and Patients with Lung Cancer: The"/>
  <result pre="changes in patients with viral pneumoniaEmerg. Microbes Infect.2020972773210.1080/22221751.2020.174619932196410 57.CafarottiS.Severe Acute" exact="Respiratory" post="Syndromeâ€&quot;Coronavirus-2 Infection and Patients with Lung Cancer: The Potential"/>
  <result pre="patients with viral pneumoniaEmerg. Microbes Infect.2020972773210.1080/22221751.2020.174619932196410 57.CafarottiS.Severe Acute Respiratory Syndromeâ€&quot;Coronavirus-2" exact="Infection" post="and Patients with Lung Cancer: The Potential Role of"/>
  <result pre="Preventive Strategies in COVID-19Vaccines2020822410.3390/vaccines802022432423059 60.XuJ.JiaW.WangP.ZhangS.ShiX.WangX.ZhangL.-Q.WangT.GoldingH.KhuranaS.Antibodies and vaccines against Middle East" exact="respiratory" post="syndrome coronavirusEmerg. Microbes Infect.2019884185610.1080/22221751.2019.162448231169078 61.RavichandranS.CoyleE.M.KlenowL.TangJ.GrubbsG.LiuS.WangT.GoldingH.KhuranaS.Antibody signature induced by SARS-CoV-2"/>
  <result pre="Strategies in COVID-19Vaccines2020822410.3390/vaccines802022432423059 60.XuJ.JiaW.WangP.ZhangS.ShiX.WangX.ZhangL.-Q.WangT.GoldingH.KhuranaS.Antibodies and vaccines against Middle East respiratory" exact="syndrome" post="coronavirusEmerg. Microbes Infect.2019884185610.1080/22221751.2019.162448231169078 61.RavichandranS.CoyleE.M.KlenowL.TangJ.GrubbsG.LiuS.WangT.GoldingH.KhuranaS.Antibody signature induced by SARS-CoV-2 spike"/>
  <result pre="rabbitsSci. Trans. Med.202012550eabc353910.1126/scitranslmed.abc353932513867 62.PremkumarL.Segovia-ChumbezB.JadiR.MartinezD.R.RautR.MarkmannA.J.CornabyC.BarteltL.WeissS.ParkY.et al.The receptor binding domain of the" exact="viral" post="spike protein is an immunodominant and highly specific target"/>
  <result pre="intensifiesNature202058125010.1038/d41586-020-01403-832393875 68.ThachilJ.SrivastavaA.SARS-2 Coronavirusâ€&quot;Associated Hemostatic Lung Abnormality in COVID-19: Is It" exact="Pulmonary" post="Thrombosis or Pulmonary Embolism?Semin. Thromb. Hemost.202010.1055/s-0040-171215532396963 69.Shimabukuro-VornhagenA.GÃ¶delP.SubkleweM.StemmlerH.J.SchlÃ¶ÃŸerH.A.SchlaakM.KochanekM.BÃ¶llB.Von Bergwelt-BaildonM.S.Cytokine release"/>
  <result pre="68.ThachilJ.SrivastavaA.SARS-2 Coronavirusâ€&quot;Associated Hemostatic Lung Abnormality in COVID-19: Is It Pulmonary" exact="Thrombosis" post="or Pulmonary Embolism?Semin. Thromb. Hemost.202010.1055/s-0040-171215532396963 69.Shimabukuro-VornhagenA.GÃ¶delP.SubkleweM.StemmlerH.J.SchlÃ¶ÃŸerH.A.SchlaakM.KochanekM.BÃ¶llB.Von Bergwelt-BaildonM.S.Cytokine release syndromeJ."/>
  <result pre="Hemostatic Lung Abnormality in COVID-19: Is It Pulmonary Thrombosis or" exact="Pulmonary" post="Embolism?Semin. Thromb. Hemost.202010.1055/s-0040-171215532396963 69.Shimabukuro-VornhagenA.GÃ¶delP.SubkleweM.StemmlerH.J.SchlÃ¶ÃŸerH.A.SchlaakM.KochanekM.BÃ¶llB.Von Bergwelt-BaildonM.S.Cytokine release syndromeJ. Immunother. Cancer201865610.1186/s40425-018-0343-929907163"/>
  <result pre="COVID-19: Consider cytokine storm syndromes and immunosuppressionLancet20203951033103410.1016/S0140-6736(20)30628-032192578 71.ZhangC.WuZ.LiJ.W.ZhaoH.WangG.Q.The cytokine release" exact="syndrome" post="(CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist"/>
  <result pre="key to reduce the mortalityInt J. Antimicrob. Agents.202010595410.1016/j.ijantimicag.2020.10595432234467 72.FehrA.R.ChannappanavarR.PerlmanS.Middle East" exact="respiratory" post="syndrome: Emergence of a pathogenic human coronavirusAnnu. Rev. Med.20176838739910.1146/annurev-med-051215-03115227576010"/>
  <result pre="interleukin-6 and severe COVID-19: A meta-analysisJ. Med. Virol.202010.1002/jmv.25948 74.MooreB.J.B.JuneC.H.Cytokine release" exact="syndrome" post="in severe COVID-19Science202036847347410.1126/science.abb892532303591 75.SchellerJ.Rose-JohnS.Interleukin-6 and its receptor: From bench"/>
  <result pre="Immunol.200619517318310.1007/s00430-006-0019-916741736 76.TanakaT.NarazakiM.KishimotoT.Immunotherapeutic implications of IL-6 blockade for cytokine stormImmunotherapy2016895997010.2217/imt-2016-002027381687 77.BekesI.WulffC.Controlling" exact="Vascular" post="Permeability: How Does It Work and What Is the"/>
  <result pre="How Does It Work and What Is the Impact on" exact="Normal" post="and Pathological AngiogenesisTumor Angiogenesis A Key Target. Cancer Ther.2019121132"/>
  <result pre="Impact on Normal and Pathological AngiogenesisTumor Angiogenesis A Key Target." exact="Cancer" post="Ther.2019121132 78.RossS.H.CantrellA.D.Signaling and Function of Interleukin-2 in T LymphocytesAnnu."/>
  <result pre="rheumatoid arthritis: A meta-analysis of efficacy and selected clinical conundrumsSemin." exact="Arthritis" post="Rheum.20144345846910.1016/j.semarthrit.2013.08.00124262929 82.YokotaS.MiyamaeT.ImagawaT.IwataN.KatakuraS.MoriM.WooP.NishimotoN.YoshizakiK.KishimotoT.Therapeutic efficacy of humanized recombinant anti-interleukin-6 receptor antibody"/>
  <result pre="of humanized recombinant anti-interleukin-6 receptor antibody in children with systemic-onset" exact="juvenile" post="idiopathic arthritisArthritis Rheum.20055281882510.1002/art.2094415751095 83.KhialiS.KhaniE.Entezari-MalekiT.A Comprehensive Review on Tocilizumab in"/>
  <result pre="idiopathic arthritisArthritis Rheum.20055281882510.1002/art.2094415751095 83.KhialiS.KhaniE.Entezari-MalekiT.A Comprehensive Review on Tocilizumab in COVID-19" exact="Acute" post="Respiratory Distress SyndromeJ. Clin. Pharmacol.202010.1002/jcph.1693 84.HuangC.WangY.LiX.RenL.ZhaoJ.HuY.Clinical features of patients"/>
  <result pre="arthritisArthritis Rheum.20055281882510.1002/art.2094415751095 83.KhialiS.KhaniE.Entezari-MalekiT.A Comprehensive Review on Tocilizumab in COVID-19 Acute" exact="Respiratory" post="Distress SyndromeJ. Clin. Pharmacol.202010.1002/jcph.1693 84.HuangC.WangY.LiX.RenL.ZhaoJ.HuY.Clinical features of patients infected"/>
  <result pre="2019 novel coronavirus in Wuhan, ChinaLancet202039549750610.1016/S0140-6736(20)30183-531986264 85.GongJ.DongH.XiaS.Q.HuangY.Z.WangD.ZhaoY.LiuW.TuS.ZhangM.WangQ.et al.Correlation Analysis Between" exact="Disease" post="Severity and Inflammation-related Parameters in Patients with COVID-19 PneumoniaMedRxiv202010.1101/2020.02.25.20025643"/>
  <result pre="factor therapy for COVID-19 are urgently neededLancet20203951407140910.1016/S0140-6736(20)30858-832278362 87.The Centers for" exact="Disease" post="Control and Prevention, Older AdultsAvailable online: https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/older-adults.html(accessed on 30"/>
  <result pre="Toronto AreaJAMA2003289280110.1001/jama.289.21.JOC3088512734147 89.AlqahtaniF.Y.AleanizyF.MohamedR.A.E.H.AlanaziM.S.MohamedN.AlrasheedM.M.AbanmyN.AlhawassiT.Prevalence of comorbidities in cases of Middle East" exact="respiratory" post="syndrome coronavirus: A retrospective studyEpidemiol. Infect.20181471510.1017/S095026881800292330394248 90.The Centers for"/>
  <result pre="AreaJAMA2003289280110.1001/jama.289.21.JOC3088512734147 89.AlqahtaniF.Y.AleanizyF.MohamedR.A.E.H.AlanaziM.S.MohamedN.AlrasheedM.M.AbanmyN.AlhawassiT.Prevalence of comorbidities in cases of Middle East respiratory" exact="syndrome" post="coronavirus: A retrospective studyEpidemiol. Infect.20181471510.1017/S095026881800292330394248 90.The Centers for Disease"/>
  <result pre="respiratory syndrome coronavirus: A retrospective studyEpidemiol. Infect.20181471510.1017/S095026881800292330394248 90.The Centers for" exact="Disease" post="Control and Prevention, People with Certain Medical ConditionsAvailable online:"/>
  <result pre="SARS-CoV-2 infectionChest202015810.1016/j.chest.2020.03.039 105.GreinJ.OhmagariN.ShinD.DiazG.AspergesE.CastagnaA.FeldtT.GreenG.GreenM.L.LescureF.-X.et al.Compassionate Use of Remdesivir for Patients with" exact="Severe" post="Covid-19N. Engl. J. Med.20203822327233610.1056/NEJMoa200701632275812 106.WangY.ZhangD.DuG.DuR.ZhaoJ.JinY.FuS.GaoL.ChengZ.LuQ.et al.Remdesivir in adults with"/>
  <result pre="of the index patient who caused tertiary transmission of coronavirus" exact="disease" post="2019 in Korea: The application of lopinavir/ritonavir for the"/>
  <result pre="Korea: The application of lopinavir/ritonavir for the treatment of COVID-19" exact="pneumonia" post="monitored by quantitative RT-PCRJ. Korean Med. Sci.202035e7910.3346/jkms.2020.35.e7932056407 111.WangZ.ChenX.LuY.ChenF.ZhangW.Clinical characteristics"/>
  <result pre="and therapeutic procedure for four cases with 2019 novel coronavirus" exact="pneumonia" post="receiving combined Chinese and Western medicine treatmentBiosci. Trends202014646810.5582/bst.2020.0103032037389 112.YoungB.E.OngS.W.X.KalimuddinS.LowJ.G.TanS.Y.LohJ.NgO.-T.MarimuthuK.AngL.W.MakT.M.et"/>
  <result pre="SingaporeJAMA202010.1001/jama.2020.320432125362 113.ZhouF.YuT.DuR.FanG.LiuY.LiuZ.XiangJ.WangY.SongB.GuX.et al.Clinical course and risk factors for mortality of" exact="adult" post="inpatients with COVID-19 in Wuhan, China: A retrospective cohort"/>
  <result pre="studyLancet20203951054106210.1016/s0140-673630566-332171076 114.CaoB.WangY.WenD.LiuW.WangJ.FanG.RuanL.SongB.CaiY.WeiM.et al.A Trial of Lopinavirâ€&quot;Ritonavir in Adults Hospitalized with" exact="Severe" post="Covid-19N. Engl. J. Med.20203821787179910.1056/NEJMoa200128232187464 115.BadenL.R.RubinE.J.Covid-19â€&quot;The Search for Effective TherapyN."/>
  <result pre="CampaignCrit. Care Med.20174548655210.1097/CCM.000000000000225528098591 118.FurutaY.KomenoT.NakamuraT.Favipiravir (T-705), a broad spectrum inhibitor of" exact="viral" post="RNA polymeraseProc. Jpn. Acad. Ser. B20179344946310.2183/pjab.93.02728769016 119.DelangL.AbdelnabiR.NeytsJ.Favipiravir as a"/>
  <result pre="a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe" exact="acute" post="respiratory syndrome coronavirus 2 with high potencyJ. Boil. Chem.20202956785679710.1074/jbc.RA120.013679"/>
  <result pre="direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute" exact="respiratory" post="syndrome coronavirus 2 with high potencyJ. Boil. Chem.20202956785679710.1074/jbc.RA120.013679 125.SidwellR.W.HuffmanJ.H.KhareG.P.AllenL.B.J.T.WitkowskiR.RobinsK.Broad-spectrum"/>
  <result pre="antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory" exact="syndrome" post="coronavirus 2 with high potencyJ. Boil. Chem.20202956785679710.1074/jbc.RA120.013679 125.SidwellR.W.HuffmanJ.H.KhareG.P.AllenL.B.J.T.WitkowskiR.RobinsK.Broad-spectrum antiviral"/>
  <result pre="application and mechanism of action of ribavirin in therapy of" exact="hepatitis" post="CAntivir. Chem. Chemother.20122311210.3851/IMP212522592135 127.GraciJ.D.CameronC.E.Mechanisms of action of ribavirin against"/>
  <result pre="130.KnowlesS.R.PhillipsE.J.DresserL.MatukasL.Common Adverse Events Associated with the Use of Ribavirin for" exact="Severe" post="Acute Respiratory Syndrome in CanadaClin. Infect. Dis.2003371139114210.1086/37830414523782 131.AltÄ±nbasS.HolmesJ.A.AltÄ±nbasA.Hepatitis C"/>
  <result pre="Adverse Events Associated with the Use of Ribavirin for Severe" exact="Acute" post="Respiratory Syndrome in CanadaClin. Infect. Dis.2003371139114210.1086/37830414523782 131.AltÄ±nbasS.HolmesJ.A.AltÄ±nbasA.Hepatitis C Virus"/>
  <result pre="Events Associated with the Use of Ribavirin for Severe Acute" exact="Respiratory" post="Syndrome in CanadaClin. Infect. Dis.2003371139114210.1086/37830414523782 131.AltÄ±nbasS.HolmesJ.A.AltÄ±nbasA.Hepatitis C Virus Infection"/>
  <result pre="Associated with the Use of Ribavirin for Severe Acute Respiratory" exact="Syndrome" post="in CanadaClin. Infect. Dis.2003371139114210.1086/37830414523782 131.AltÄ±nbasS.HolmesJ.A.AltÄ±nbasA.Hepatitis C Virus Infection in"/>
  <result pre="Acute Respiratory Syndrome in CanadaClin. Infect. Dis.2003371139114210.1086/37830414523782 131.AltÄ±nbasS.HolmesJ.A.AltÄ±nbasA.Hepatitis C Virus" exact="Infection" post="in PregnancyGastroenterol. Nurs.202043122110.1097/SGA.000000000000040431990870 132.ZhangQ.WangY.QiC.ShenL.LiJ.Clinical trial analysis of 2019-nCoV therapy"/>
  <result pre="ChinaJ. Med. Virol.20209254054510.1002/jmv.2573332108352 133.BoriskinY.LenevaI.PecheurE.-I.PolyÃ¡kS.Arbidol: A Broad-Spectrum Antiviral Compound that Blocks" exact="Viral" post="FusionCurr. Med. Chem.200815997100510.2174/09298670878404965818393857 134.BlaisingJ.PolyakS.J.PÃ©cheurE.-I.Arbidol as a broad-spectrum antiviral: An"/>
  <result pre="of arbidol and its derivatives against the pathogen of severe" exact="acute" post="respiratory syndrome in the cell culturesVopr. Virusol.200853913 137.WangZ.YangB.LiQ.WenL.ZhangR.Clinical Features"/>
  <result pre="arbidol and its derivatives against the pathogen of severe acute" exact="respiratory" post="syndrome in the cell culturesVopr. Virusol.200853913 137.WangZ.YangB.LiQ.WenL.ZhangR.Clinical Features of"/>
  <result pre="and its derivatives against the pathogen of severe acute respiratory" exact="syndrome" post="in the cell culturesVopr. Virusol.200853913 137.WangZ.YangB.LiQ.WenL.ZhangR.Clinical Features of 69"/>
  <result pre="cell culturesVopr. Virusol.200853913 137.WangZ.YangB.LiQ.WenL.ZhangR.Clinical Features of 69 Cases With Coronavirus" exact="Disease" post="2019 in Wuhan, ChinaClin. Infect. Dis.202010.1093/cid/ciaa272 138.McKeeD.L.SternbergA.StangeU.LauferS.NaujokatC.Candidate drugs against"/>
  <result pre="and SARS-Coronavirus Activating Proteases TMPRSS2 and HAT Are Expressed at" exact="Multiple" post="Sites in Human Respiratory and Gastrointestinal TractsPLoS ONE20127e3587610.1371/journal.pone.003587622558251 140.MatsuyamaS.NagataN.ShiratoK.KawaseM.TakedaM.TaguchiF.Efficient"/>
  <result pre="TMPRSS2 and HAT Are Expressed at Multiple Sites in Human" exact="Respiratory" post="and Gastrointestinal TractsPLoS ONE20127e3587610.1371/journal.pone.003587622558251 140.MatsuyamaS.NagataN.ShiratoK.KawaseM.TakedaM.TaguchiF.Efficient Activation of the Severe"/>
  <result pre="Human Respiratory and Gastrointestinal TractsPLoS ONE20127e3587610.1371/journal.pone.003587622558251 140.MatsuyamaS.NagataN.ShiratoK.KawaseM.TakedaM.TaguchiF.Efficient Activation of the" exact="Severe" post="Acute Respiratory Syndrome Coronavirus Spike Protein by the Transmembrane"/>
  <result pre="Respiratory and Gastrointestinal TractsPLoS ONE20127e3587610.1371/journal.pone.003587622558251 140.MatsuyamaS.NagataN.ShiratoK.KawaseM.TakedaM.TaguchiF.Efficient Activation of the Severe" exact="Acute" post="Respiratory Syndrome Coronavirus Spike Protein by the Transmembrane Protease"/>
  <result pre="and Gastrointestinal TractsPLoS ONE20127e3587610.1371/journal.pone.003587622558251 140.MatsuyamaS.NagataN.ShiratoK.KawaseM.TakedaM.TaguchiF.Efficient Activation of the Severe Acute" exact="Respiratory" post="Syndrome Coronavirus Spike Protein by the Transmembrane Protease TMPRSS2J."/>
  <result pre="Gastrointestinal TractsPLoS ONE20127e3587610.1371/journal.pone.003587622558251 140.MatsuyamaS.NagataN.ShiratoK.KawaseM.TakedaM.TaguchiF.Efficient Activation of the Severe Acute Respiratory" exact="Syndrome" post="Coronavirus Spike Protein by the Transmembrane Protease TMPRSS2J. Virol.201084126581266410.1128/JVI.01542-1020926566"/>
  <result pre="140.MatsuyamaS.NagataN.ShiratoK.KawaseM.TakedaM.TaguchiF.Efficient Activation of the Severe Acute Respiratory Syndrome Coronavirus Spike" exact="Protein" post="by the Transmembrane Protease TMPRSS2J. Virol.201084126581266410.1128/JVI.01542-1020926566 141.ZhouY.VedanthamP.LuK.AgudeloJ.CarrionR.NunneleyJ.W.BarnardD.PÃ¶hlmannS.McKerrowJ.H.RensloA.R.et al.Protease inhibitors"/>
  <result pre="Bronchial Epithelial Cells with Serine and Cysteine Protease Inhibitors Prevents" exact="Severe" post="Acute Respiratory Syndrome Coronavirus EntryJ. Virol.2012866537654510.1128/JVI.00094-1222496216 143.HoffmannM.Kleine-WeberH.SchroederS.KrÃ¼gerN.HerrlerT.ErichsenS.SchiergensT.S.HerrlerG.WuN.-H.NitscheA.et al.SARS-CoV-2 Cell"/>
  <result pre="Epithelial Cells with Serine and Cysteine Protease Inhibitors Prevents Severe" exact="Acute" post="Respiratory Syndrome Coronavirus EntryJ. Virol.2012866537654510.1128/JVI.00094-1222496216 143.HoffmannM.Kleine-WeberH.SchroederS.KrÃ¼gerN.HerrlerT.ErichsenS.SchiergensT.S.HerrlerG.WuN.-H.NitscheA.et al.SARS-CoV-2 Cell Entry"/>
  <result pre="Cells with Serine and Cysteine Protease Inhibitors Prevents Severe Acute" exact="Respiratory" post="Syndrome Coronavirus EntryJ. Virol.2012866537654510.1128/JVI.00094-1222496216 143.HoffmannM.Kleine-WeberH.SchroederS.KrÃ¼gerN.HerrlerT.ErichsenS.SchiergensT.S.HerrlerG.WuN.-H.NitscheA.et al.SARS-CoV-2 Cell Entry Depends"/>
  <result pre="with Serine and Cysteine Protease Inhibitors Prevents Severe Acute Respiratory" exact="Syndrome" post="Coronavirus EntryJ. Virol.2012866537654510.1128/JVI.00094-1222496216 143.HoffmannM.Kleine-WeberH.SchroederS.KrÃ¼gerN.HerrlerT.ErichsenS.SchiergensT.S.HerrlerG.WuN.-H.NitscheA.et al.SARS-CoV-2 Cell Entry Depends on"/>
  <result pre="nafamostat mesilate. V. Effects on the pancreatic enzymes and experimental" exact="acute" post="pancreatitis in ratsJpn. J. Pharmacol.19864115516210.1254/jjp.41.1552427760 145.ChenX.XuZ.ZengS.WangX.LiuW.QianL.WeiJ.YangX.ShenQ.GongZ.et al.The Molecular Aspect"/>
  <result pre="mesilate. V. Effects on the pancreatic enzymes and experimental acute" exact="pancreatitis" post="in ratsJpn. J. Pharmacol.19864115516210.1254/jjp.41.1552427760 145.ChenX.XuZ.ZengS.WangX.LiuW.QianL.WeiJ.YangX.ShenQ.GongZ.et al.The Molecular Aspect of"/>
  <result pre="Antimicrob. Agents20205510593810.1016/j.ijantimicag.2020.10593832171740 148.VincentM.J.BergeronE.BenjannetS.EricksonB.R.RollinP.E.KsiazekT.G.SeidahN.G.NicholS.T.Chloroquine is a potent inhibitor of SARS coronavirus" exact="infection" post="and spreadVirol. J.200526910.1186/1743-422X-2-6916115318 149.SinghA.K.SinghA.ShaikhA.SinghR.MisraA.Chloroquine and hydroxychloroquine in the treatment"/>
  <result pre="countriesDiabetes Metab. Syndr. Clin. Res. Rev.20201424124610.1016/j.dsx.2020.03.01132247211 150.SavarinoA.BoelaertJ.R.CassoneA.MajoriG.CaudaR.Effects of chloroquine on" exact="viral" post="infections: An old drug against todayâ€™s diseasesLancet Infect. Dis.2003372272710.1016/S1473-3099(03)00806-514592603"/>
  <result pre="Antimicrob. Agents20205510593210.1016/j.ijantimicag.2020.10593232145363 152.BernsteinH.N.Ocular safety of hydroxychloroquineAnn. Ophthalmol.1991232922961952638 153.RatliffN.B.EstesM.L.MylesJ.L.ShireyE.K.McMahonJ.T.Diagnosis of Chloroquine" exact="Cardiomyopathy" post="by Endomyocardial BiopsyN. Engl. J. Med.198731619119310.1056/NEJM1987012231604053796692 154.McChesneyE.W.Animal toxicity and"/>
  <result pre="analogs as a promising strategy for the treatment of emerging" exact="viral" post="diseasesPharmacol. Res. Perspect.20175e0029310.1002/prp2.29328596841 156.BiotC.DaherW.ChavainN.FandeurT.KhalifeJ.DiveD.De ClercqE.Design and Synthesis of Hydroxyferroquine"/>
  <result pre="of Optimized Dosing Design of Hydroxychloroquine for the Treatment of" exact="Severe" post="Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)Clin. Infect. Dis.202010.1093/cid/ciaa237 158.GautretP.LagierJ.-C.ParolaP.HoangV.T.MeddebL.MailheM.DoudierB.CourjonJ.GiordanengoV.VieiraV.E.et"/>
  <result pre="Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe" exact="Acute" post="Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)Clin. Infect. Dis.202010.1093/cid/ciaa237 158.GautretP.LagierJ.-C.ParolaP.HoangV.T.MeddebL.MailheM.DoudierB.CourjonJ.GiordanengoV.VieiraV.E.et al.Hydroxychloroquine"/>
  <result pre="Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute" exact="Respiratory" post="Syndrome Coronavirus 2 (SARS-CoV-2)Clin. Infect. Dis.202010.1093/cid/ciaa237 158.GautretP.LagierJ.-C.ParolaP.HoangV.T.MeddebL.MailheM.DoudierB.CourjonJ.GiordanengoV.VieiraV.E.et al.Hydroxychloroquine and"/>
  <result pre="Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory" exact="Syndrome" post="Coronavirus 2 (SARS-CoV-2)Clin. Infect. Dis.202010.1093/cid/ciaa237 158.GautretP.LagierJ.-C.ParolaP.HoangV.T.MeddebL.MailheM.DoudierB.CourjonJ.GiordanengoV.VieiraV.E.et al.Hydroxychloroquine and azithromycin"/>
  <result pre="Hospital Setting or a Clinical Trial Due to Risk of" exact="Heart" post="Rhythm Problems172020Available online: https://www.fda.gov/drugs/drug-safety-and-availability/fda-cautions-against-use-hydroxychloroquine-or-chloroquine-covid-19-outside-hospital-setting-or(accessed on 1 July 2020) 164.No"/>
  <result pre="5 June 2020) 165.collab: Health. NIoCOVID-19 Treatment Guidelines Panel. Coronavirus" exact="Disease" post="2019 (COVID-19) Treatment Guidelines1662020Available online: https://www.covid19treatmentguidelines.nih.gov/(accessed on 30 July"/>
  <result pre="171.MaranoG.VaglioS.PupellaS.FaccoG.CatalanoL.LiumbrunoG.M.GrazziniG.Convalescent plasma: New evidence for an old therapeutic tool?High Speed" exact="Blood" post="Transfus. Equip.201514152157 172.ChaudhuriS.SymonsJ.A.DevalJ.Innovation and trends in the development and"/>
  <result pre="beyondAntivir. Res.2018155768810.1016/j.antiviral.2018.05.00529758235 173.RosenkeK.E.BoundsC.HanleyP.W.SaturdayG.SullivanE.WuH.JiaoJ.-A.FeldmannH.SchmaljohnC.SafronetzD.Human Polyclonal Antibodies Produced by Transchromosomal Cattle Provide" exact="Partial" post="Protection Against Lethal Zaire Ebolavirus Challenge in Rhesus MacaquesJ."/>
  <result pre="Res.2018155768810.1016/j.antiviral.2018.05.00529758235 173.RosenkeK.E.BoundsC.HanleyP.W.SaturdayG.SullivanE.WuH.JiaoJ.-A.FeldmannH.SchmaljohnC.SafronetzD.Human Polyclonal Antibodies Produced by Transchromosomal Cattle Provide Partial" exact="Protection Against" post="Lethal Zaire Ebolavirus Challenge in Rhesus MacaquesJ. Infect. Dis.2018218S658S66110.1093/infdis/jiy43030053153"/>
  <result pre="Polyclonal Antibodies Produced by Transchromosomal Cattle Provide Partial Protection Against" exact="Lethal" post="Zaire Ebolavirus Challenge in Rhesus MacaquesJ. Infect. Dis.2018218S658S66110.1093/infdis/jiy43030053153 174.ZhangJ.-S.ChenJ.-T.LiuY.-X.ZhangZ.-S.GaoH.LiuY.WangX.NingY.LiuY.-F.GaoQ.et"/>
  <result pre="Virol.20057714715010.1002/jmv.2043116121363 175.Van GriensvenJ.EdwardsT.De LamballerieX.SempleM.G.GallianP.BaizeS.HorbyP.RaoulH.MagassoubaN.AntierensA.et al.Evaluation of Convalescent Plasma for Ebola" exact="Virus Disease" post="in GuineaN. Engl. J. Med.2016374334210.1056/NEJMoa151181226735992 176.AnudeepT.JeyaramanM.ShettyD.U.RajH.AjayS.Rajeswari SomasundaramV.K.V.KumarV.JainR.ShirodkarJ.Convalescent Plasma as"/>
  <result pre="175.Van GriensvenJ.EdwardsT.De LamballerieX.SempleM.G.GallianP.BaizeS.HorbyP.RaoulH.MagassoubaN.AntierensA.et al.Evaluation of Convalescent Plasma for Ebola Virus" exact="Disease" post="in GuineaN. Engl. J. Med.2016374334210.1056/NEJMoa151181226735992 176.AnudeepT.JeyaramanM.ShettyD.U.RajH.AjayS.Rajeswari SomasundaramV.K.V.KumarV.JainR.ShirodkarJ.Convalescent Plasma as"/>
  <result pre="Infect. Dis.200424444610.1007/s10096-004-1271-915616839 179.YehK.-M.ChiuehT.-S.SiuL.K.LinJ.-C.ChanP.K.PengM.-Y.WanH.-L.ChenJ.-H.HuB.-S.PerngC.-L.et al.Experience of using convalescent plasma for severe" exact="acute" post="respiratory syndrome among healthcare workers in a Taiwan hospitalJ."/>
  <result pre="Dis.200424444610.1007/s10096-004-1271-915616839 179.YehK.-M.ChiuehT.-S.SiuL.K.LinJ.-C.ChanP.K.PengM.-Y.WanH.-L.ChenJ.-H.HuB.-S.PerngC.-L.et al.Experience of using convalescent plasma for severe acute" exact="respiratory" post="syndrome among healthcare workers in a Taiwan hospitalJ. Antimicrob."/>
  <result pre="179.YehK.-M.ChiuehT.-S.SiuL.K.LinJ.-C.ChanP.K.PengM.-Y.WanH.-L.ChenJ.-H.HuB.-S.PerngC.-L.et al.Experience of using convalescent plasma for severe acute respiratory" exact="syndrome" post="among healthcare workers in a Taiwan hospitalJ. Antimicrob. Chemother.20055691992210.1093/jac/dki34616183666"/>
  <result pre="180.KoJ.-H.SeokH.ChoS.Y.HaY.E.BaekJ.Y.KimS.H.KimY.-J.ParkJ.K.ChungC.R.KangE.-S.et al.Challenges of convalescent plasma infusion therapy in Middle East" exact="respiratory" post="coronavirus infection: A single centre experienceAntivir. Ther.20182361762210.3851/IMP324329923831 181.ZhangL.PangR.XueX.BaoJ.YeS.DaiY.ZhengY.FuQ.HuZ.YiY.Anti-SARS-CoV-2 virus"/>
  <result pre="recovered from COVID-19Aging2020126536654210.18632/aging.10310232320384 182.The Efficacy of Intravenous Immunoglobulin Therapy for" exact="Severe" post="2019-nCoV Infected PneumoniaAvailable online: https://clinicaltrials.gov/ct2/show/NCT04261426(accessed on 3 August 2020)"/>
  <result pre="of COVID-19Available online: https://clinicaltrials.gov/ct2/show/NCT04292340(accessed on 3 August 2020) 184.Treatment of" exact="Acute" post="Severe 2019-nCoV Pneumonia with Immunoglobulin from Cured PatientsAvailable online:"/>
  <result pre="COVID-19Available online: https://clinicaltrials.gov/ct2/show/NCT04292340(accessed on 3 August 2020) 184.Treatment of Acute" exact="Severe" post="2019-nCoV Pneumonia with Immunoglobulin from Cured PatientsAvailable online: https://www.clinicaltrials.gov/ct2/show/NCT04264858(accessed"/>
  <result pre="https://clinicaltrials.gov/ct2/show/NCT04292340(accessed on 3 August 2020) 184.Treatment of Acute Severe 2019-nCoV" exact="Pneumonia" post="with Immunoglobulin from Cured PatientsAvailable online: https://www.clinicaltrials.gov/ct2/show/NCT04264858(accessed on 3"/>
  <result pre="intravenous immunoglobulins (IVIg)â€&quot;Beyond immunodeficiencies and neurologyClin. Exp. Immunol.2009158233310.1111/j.1365-2249.2009.04024.x19883421 191.KazatchkineM.D.KaveriS.Immunomodulation of" exact="Autoimmune" post="and Inflammatory Diseases with Intravenous Immune GlobulinN. Engl. J."/>
  <result pre="(IVIg)â€&quot;Beyond immunodeficiencies and neurologyClin. Exp. Immunol.2009158233310.1111/j.1365-2249.2009.04024.x19883421 191.KazatchkineM.D.KaveriS.Immunomodulation of Autoimmune and" exact="Inflammatory" post="Diseases with Intravenous Immune GlobulinN. Engl. J. Med.200134574775510.1056/NEJMra99336011547745 192.FerraraG.ZumlaA.MaeurerM.Intravenous"/>
  <result pre="immunodeficiencies and neurologyClin. Exp. Immunol.2009158233310.1111/j.1365-2249.2009.04024.x19883421 191.KazatchkineM.D.KaveriS.Immunomodulation of Autoimmune and Inflammatory" exact="Diseases" post="with Intravenous Immune GlobulinN. Engl. J. Med.200134574775510.1056/NEJMra99336011547745 192.FerraraG.ZumlaA.MaeurerM.Intravenous Immunoglobulin"/>
  <result pre="Intravenous Immune GlobulinN. Engl. J. Med.200134574775510.1056/NEJMra99336011547745 192.FerraraG.ZumlaA.MaeurerM.Intravenous Immunoglobulin (IVIg) for" exact="Refractory" post="and Difficult-to-treat InfectionsAm. J. Med.20121251036.e11036.e810.1016/j.amjmed.2012.01.02322608788 193.StockmanL.J.BellamyR.GarnerP.SARS: Systematic Review of"/>
  <result pre="role of peptides as potential therapeutic components for Middle East" exact="Respiratory" post="Syndrome (MERS): A reviewJ. Infect. Public Health20181191710.1016/j.jiph.2017.08.00928864360 195.ChongY.P.SongJ.Y.Bin SeoY.ChoiJ.-P.ShinH.-S.TeamR.R.Antiviral"/>
  <result pre="of peptides as potential therapeutic components for Middle East Respiratory" exact="Syndrome" post="(MERS): A reviewJ. Infect. Public Health20181191710.1016/j.jiph.2017.08.00928864360 195.ChongY.P.SongJ.Y.Bin SeoY.ChoiJ.-P.ShinH.-S.TeamR.R.Antiviral Treatment"/>
  <result pre="Infect. Public Health20181191710.1016/j.jiph.2017.08.00928864360 195.ChongY.P.SongJ.Y.Bin SeoY.ChoiJ.-P.ShinH.-S.TeamR.R.Antiviral Treatment Guidelines for Middle East" exact="Respiratory" post="SyndromeInfect. Chemother.20154721222210.3947/ic.2015.47.3.21226483999 196.ShiH.ZhouC.HeP.HuangS.DuanY.WangX.LinK.ZhouC.ZhangX.ZhaY.Successful treatment of plasma exchange followed by"/>
  <result pre="198.XieY.CaoS.DongH.LiQ.ChenE.ZhangW.YangL.FuS.WangR.Effect of regular intravenous immunoglobulin therapy on prognosis of severe" exact="pneumonia" post="in patients with COVID-19J. Infect.202010.1016/j.jinf.2020.03.044 199.ShanmugarajB.SiriwattananonK.WangkanontK.PhoolcharoenW.Perspectives on monoclonal antibody"/>
  <result pre="efficacy and safety of sarilumab combination therapy in patients with" exact="rheumatoid arthritis" post="with inadequate response to conventional disease-modifying antirheumatic drugs or"/>
  <result pre="and safety of sarilumab combination therapy in patients with rheumatoid" exact="arthritis" post="with inadequate response to conventional disease-modifying antirheumatic drugs or"/>
  <result pre="J. Antimicrobial Agents202010.1016/j.ijantimicag.2020.10596732259575 206.NieJ.WangC.LiuY.YangQ.MeiQ.DongL.LiX.LiuJ.KuW.ZhangY.et al.Addition of Low-Dose Decitabine to Antiâ€&quot;PD-1" exact="Antibody" post="Camrelizumab in Relapsed/Refractory Classical Hodgkin LymphomaJ. Clin. Oncol.2019371479148910.1200/JCO.18.0215131039052 207.BlairH.A.Ibalizumab:"/>
  <result pre="A new pattern of drug-associated lung toxicity?Respirat. Med. Rep.20161911812010.1016/j.rmcr.2016.09.001 209.WangZ.ChenT.LinW.ZhengW.ChenJ.HuangF.XieX.Functional" exact="tumor" post="specific CD8 + T cells in spleen express a"/>
  <result pre="and the use of immunomodulatory and biologic agents for severe" exact="cutaneous" post="disease: An Australia/New Zealand consensus statementAustral. J. Dermatol.202010.1111/ajd.13313 211.De"/>
  <result pre="Dermatol.202010.1111/ajd.13313 211.De LucaG.CavalliG.CampochiaroC.Della-TorreE.AngelilloP.TomelleriA.BoffiniN.TentoriS.MetteF.FarinaN.et al.GM-CSF blockade with mavrilimumab in severe COVID-19" exact="pneumonia" post="and systemic hyperinflammation: A single-centre, prospective cohort studyLancet Rheumatol.202010.1016/S2665-9913(20)30170-3"/>
  <result pre="LucaG.CavalliG.CampochiaroC.Della-TorreE.AngelilloP.TomelleriA.BoffiniN.TentoriS.MetteF.FarinaN.et al.GM-CSF blockade with mavrilimumab in severe COVID-19 pneumonia and" exact="systemic" post="hyperinflammation: A single-centre, prospective cohort studyLancet Rheumatol.202010.1016/S2665-9913(20)30170-3 212.JiangS.HillyerC.DuL.J.T.Neutralizing antibodies"/>
  <result pre="Systematic ReviewCurr. Ther. Res.201784102110.1016/j.curtheres.2017.01.00728761574 217.GielenV.JohnstonS.L.EdwardsM.R.Azithromycin induces anti-viral responses in bronchial" exact="epithelial" post="cellsEur. Respir. J.20103664665410.1183/09031936.0009580920150207 218.LiC.ZuS.DengY.-Q.LiD.ParvatiyarK.QuanquinN.ShangJ.SunN.SuJ.LiuZ.et al.Azithromycin Protects against Zika Virus"/>
  <result pre="epithelial cellsEur. Respir. J.20103664665410.1183/09031936.0009580920150207 218.LiC.ZuS.DengY.-Q.LiD.ParvatiyarK.QuanquinN.ShangJ.SunN.SuJ.LiuZ.et al.Azithromycin Protects against Zika Virus" exact="Infection" post="by Upregulating Virus-Induced Type I and III Interferon ResponsesAntimicrob."/>
  <result pre="218.LiC.ZuS.DengY.-Q.LiD.ParvatiyarK.QuanquinN.ShangJ.SunN.SuJ.LiuZ.et al.Azithromycin Protects against Zika Virus Infection by Upregulating Virus-Induced" exact="Type I" post="and III Interferon ResponsesAntimicrob. Agents Chemother.20196310.1128/AAC.00394-19 219.TranD.H.SugamataR.HiroseT.SuzukiS.NoguchiY.SugawaraA.ItoF.YamamotoT.KawachiS.AkagawaK.S.et al.Azithromycin, a"/>
  <result pre="Chemother.20196310.1128/AAC.00394-19 219.TranD.H.SugamataR.HiroseT.SuzukiS.NoguchiY.SugawaraA.ItoF.YamamotoT.KawachiS.AkagawaK.S.et al.Azithromycin, a 15-membered macrolide antibiotic, inhibits influenza A(H1N1)pdm09" exact="virus infection" post="by interfering with virus internalization processJ. Antibiot.20197275976810.1038/s41429-019-0204-x31300721 220.BarnesP.J.How corticosteroids"/>
  <result pre="219.TranD.H.SugamataR.HiroseT.SuzukiS.NoguchiY.SugawaraA.ItoF.YamamotoT.KawachiS.AkagawaK.S.et al.Azithromycin, a 15-membered macrolide antibiotic, inhibits influenza A(H1N1)pdm09 virus" exact="infection" post="by interfering with virus internalization processJ. Antibiot.20197275976810.1038/s41429-019-0204-x31300721 220.BarnesP.J.How corticosteroids"/>
  <result pre="al.Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirusâ€&quot;Infected" exact="Pneumonia" post="in Wuhan, ChinaJAMA2020323106110.1001/jama.2020.158532031570 223.RodrigoC.Leonardi-BeeJ.Nguyen-Van-TamJ.LimW.S.Effect of Corticosteroid Therapy on Influenza-Related"/>
  <result pre="224.ArabiY.MandourahY.Al-HameedF.SindiA.A.AlmekhlafiG.A.HusseinM.JoseJ.PintoR.Al-OmariA.KharabaA.et al.Corticosteroid Therapy for Critically Ill Patients with Middle East" exact="Respiratory" post="SyndromeAm. J. Respir. Crit. Care Med.201819775776710.1164/rccm.201706-1172OC29161116 225.YangZ.LiuJ.ZhouY.ZhaoX.ZhaoQ.LiuJ.The effect of"/>
  <result pre="review and meta-analysisJ. Infect.202081e13e2010.1016/j.jinf.2020.03.06232283144 226.ZhaL.LiS.PanL.TefsenB.LiY.FrenchN.ChenL.YangG.VillanuevaE.V.Corticosteroid treatment of patients with coronavirus" exact="disease" post="2019 (COVID -19)Med. J. Aust.202021241642010.5694/mja2.5057732266987 227.FangX.MeiQ.YangT.LiL.WangY.TongF.GengS.PanA.Low-dose corticosteroid therapy does"/>
  <result pre="(COVID -19)Med. J. Aust.202021241642010.5694/mja2.5057732266987 227.FangX.MeiQ.YangT.LiL.WangY.TongF.GengS.PanA.Low-dose corticosteroid therapy does not delay" exact="viral" post="clearance in patients with COVID-19J. Infect.202010.1016/j.jinf.2020.03.039 228.World Health Organization"/>
  <result pre="with COVID-19J. Infect.202010.1016/j.jinf.2020.03.039 228.World Health Organization Clinical management of severe" exact="acute" post="respiratory infection (SARI) when COVID-19 disease is suspected. Interim"/>
  <result pre="COVID-19J. Infect.202010.1016/j.jinf.2020.03.039 228.World Health Organization Clinical management of severe acute" exact="respiratory" post="infection (SARI) when COVID-19 disease is suspected. Interim guidancePediatr."/>
  <result pre="Infect.202010.1016/j.jinf.2020.03.039 228.World Health Organization Clinical management of severe acute respiratory" exact="infection" post="(SARI) when COVID-19 disease is suspected. Interim guidancePediatr. Med."/>
  <result pre="Clinical management of severe acute respiratory infection (SARI) when COVID-19" exact="disease" post="is suspected. Interim guidancePediatr. Med. Rodz.20201692610.15557/PiMR.2020.0003 229.LedfordH.Coronavirus breakthrough: Dexamethasone"/>
  <result pre="therapeutic potentialCardiovasc. Res.20025525026010.1016/S0008-6363(02)00327-912123764 232.Ã…kerstroÃ¶mS.Mousavi-JaziM.KlingstromJ.LeijonM.LundkvistA.MirazimiA.Nitric Oxide Inhibits the Replication Cycle of" exact="Severe" post="Acute Respiratory Syndrome CoronavirusJ. Virol.2005791966196910.1128/jvi.79.3.1966-1969.200515650225 233.KeyaertsE.VijgenL.ChenL.MaesP.HedenstiernaG.Van RanstM.Inhibition of SARS-coronavirus"/>
  <result pre="potentialCardiovasc. Res.20025525026010.1016/S0008-6363(02)00327-912123764 232.Ã…kerstroÃ¶mS.Mousavi-JaziM.KlingstromJ.LeijonM.LundkvistA.MirazimiA.Nitric Oxide Inhibits the Replication Cycle of Severe" exact="Acute" post="Respiratory Syndrome CoronavirusJ. Virol.2005791966196910.1128/jvi.79.3.1966-1969.200515650225 233.KeyaertsE.VijgenL.ChenL.MaesP.HedenstiernaG.Van RanstM.Inhibition of SARS-coronavirus infection"/>
  <result pre="Res.20025525026010.1016/S0008-6363(02)00327-912123764 232.Ã…kerstroÃ¶mS.Mousavi-JaziM.KlingstromJ.LeijonM.LundkvistA.MirazimiA.Nitric Oxide Inhibits the Replication Cycle of Severe Acute" exact="Respiratory" post="Syndrome CoronavirusJ. Virol.2005791966196910.1128/jvi.79.3.1966-1969.200515650225 233.KeyaertsE.VijgenL.ChenL.MaesP.HedenstiernaG.Van RanstM.Inhibition of SARS-coronavirus infection in"/>
  <result pre="232.Ã…kerstroÃ¶mS.Mousavi-JaziM.KlingstromJ.LeijonM.LundkvistA.MirazimiA.Nitric Oxide Inhibits the Replication Cycle of Severe Acute Respiratory" exact="Syndrome" post="CoronavirusJ. Virol.2005791966196910.1128/jvi.79.3.1966-1969.200515650225 233.KeyaertsE.VijgenL.ChenL.MaesP.HedenstiernaG.Van RanstM.Inhibition of SARS-coronavirus infection in vitro"/>
  <result pre="Severe Acute Respiratory Syndrome CoronavirusJ. Virol.2005791966196910.1128/jvi.79.3.1966-1969.200515650225 233.KeyaertsE.VijgenL.ChenL.MaesP.HedenstiernaG.Van RanstM.Inhibition of SARS-coronavirus" exact="infection" post="in vitro by S-nitroso-N-acetylpenicillamine, a nitric oxide donor compoundInt."/>
  <result pre="Infect. Dis.2004822322610.1016/j.ijid.2004.04.01215234326 234.DellingerR.P.TrzeciakS.CrinerG.ZimmermanJ.L.TaylorR.W.UsanskyH.YoungJ.GoldsteinB.Association between inhaled nitric oxide treatment and long-term" exact="pulmonary" post="function in survivors of acute respiratory distress syndromeCrit. Care201216R3610.1186/cc1121522386043"/>
  <result pre="nitric oxide treatment and long-term pulmonary function in survivors of" exact="acute" post="respiratory distress syndromeCrit. Care201216R3610.1186/cc1121522386043 235.Ã…kerstrÃ¶mS.GunalanV.KengC.T.TanY.-J.MirazimiA.Dual effect of nitric oxide"/>
  <result pre="oxide treatment and long-term pulmonary function in survivors of acute" exact="respiratory" post="distress syndromeCrit. Care201216R3610.1186/cc1121522386043 235.Ã…kerstrÃ¶mS.GunalanV.KengC.T.TanY.-J.MirazimiA.Dual effect of nitric oxide on"/>
  <result pre="syndromeCrit. Care201216R3610.1186/cc1121522386043 235.Ã…kerstrÃ¶mS.GunalanV.KengC.T.TanY.-J.MirazimiA.Dual effect of nitric oxide on SARS-CoV replication:" exact="Viral" post="RNA production and palmitoylation of the S protein are"/>
  <result pre="are affectedVirology20093951910.1016/j.virol.2009.09.00719800091 236.ChenL.LiuP.GaoH.SunB.ChaoD.WangF.ZhuY.HedenstiernaG.WangC.G.Inhalation of Nitric Oxide in the Treatment of" exact="Severe" post="Acute Respiratory Syndrome: A Rescue Trial in BeijingClin. Infect."/>
  <result pre="affectedVirology20093951910.1016/j.virol.2009.09.00719800091 236.ChenL.LiuP.GaoH.SunB.ChaoD.WangF.ZhuY.HedenstiernaG.WangC.G.Inhalation of Nitric Oxide in the Treatment of Severe" exact="Acute" post="Respiratory Syndrome: A Rescue Trial in BeijingClin. Infect. Dis.2004391531153510.1086/42535715546092"/>
  <result pre="236.ChenL.LiuP.GaoH.SunB.ChaoD.WangF.ZhuY.HedenstiernaG.WangC.G.Inhalation of Nitric Oxide in the Treatment of Severe Acute" exact="Respiratory" post="Syndrome: A Rescue Trial in BeijingClin. Infect. Dis.2004391531153510.1086/42535715546092 237.KakodkarP.KakaN.BaigM.A"/>
  <result pre="on the Clinical Presentation, and Management of the Pandemic Coronavirus" exact="Disease" post="2019 (COVID-19)Cureus20201210.7759/cureus.7560 238.DongL.HuS.GaoJ.Discovering drugs to treat coronavirus disease 2019"/>
  <result pre="Pandemic Coronavirus Disease 2019 (COVID-19)Cureus20201210.7759/cureus.7560 238.DongL.HuS.GaoJ.Discovering drugs to treat coronavirus" exact="disease" post="2019 (COVID-19)Drug Discov. Ther.202014586010.5582/ddt.2020.0101232147628 239.SandersJ.M.MonogueM.L.JodlowskiT.Z.CutrellJ.B.Pharmacologic Treatments for Coronavirus Disease"/>
  <result pre="coronavirus disease 2019 (COVID-19)Drug Discov. Ther.202014586010.5582/ddt.2020.0101232147628 239.SandersJ.M.MonogueM.L.JodlowskiT.Z.CutrellJ.B.Pharmacologic Treatments for Coronavirus" exact="Disease" post="2019 (COVID-19): A ReviewJAMA202010.1001/jama.2020.6019 240.UnoY.Camostat mesilate therapy for COVID-19Intern."/>
  <result pre="diameter with a 26â€&quot;32 kb single stranded RNA (ssRNA) genome." exact="Severe" post="acute respiratory syndrome coronavirus (SARS-CoV), Middle East respiratory syndrome"/>
  <result pre="with a 26â€&quot;32 kb single stranded RNA (ssRNA) genome. Severe" exact="acute" post="respiratory syndrome coronavirus (SARS-CoV), Middle East respiratory syndrome coronavirus"/>
  <result pre="a 26â€&quot;32 kb single stranded RNA (ssRNA) genome. Severe acute" exact="respiratory" post="syndrome coronavirus (SARS-CoV), Middle East respiratory syndrome coronavirus (MERS-CoV)"/>
  <result pre="26â€&quot;32 kb single stranded RNA (ssRNA) genome. Severe acute respiratory" exact="syndrome" post="coronavirus (SARS-CoV), Middle East respiratory syndrome coronavirus (MERS-CoV) and"/>
  <result pre="(ssRNA) genome. Severe acute respiratory syndrome coronavirus (SARS-CoV), Middle East" exact="respiratory" post="syndrome coronavirus (MERS-CoV) and severe acute respiratory syndrome coronavirus"/>
  <result pre="genome. Severe acute respiratory syndrome coronavirus (SARS-CoV), Middle East respiratory" exact="syndrome" post="coronavirus (MERS-CoV) and severe acute respiratory syndrome coronavirus 2"/>
  <result pre="coronavirus (SARS-CoV), Middle East respiratory syndrome coronavirus (MERS-CoV) and severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2) share a common open"/>
  <result pre="(SARS-CoV), Middle East respiratory syndrome coronavirus (MERS-CoV) and severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2) share a common open reading"/>
  <result pre="Middle East respiratory syndrome coronavirus (MERS-CoV) and severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2) share a common open reading frame"/>
  <result pre="(ACE2). Following a conformation change in the S protein, the" exact="viral" post="envelope fuses with the cell membrane. After endocytosis, the"/>
  <result pre="Genomic RNA, which is positive sense, is translated into the" exact="viral" post="polyproteins pp1a and 1ab. The polymerase produces a series"/>
  <result pre="produces a series of subgenomic mRNAs and translates the relevant" exact="viral" post="proteins. In the endoplasmic reticulum (ER) and Golgi, viral"/>
  <result pre="relevant viral proteins. In the endoplasmic reticulum (ER) and Golgi," exact="viral" post="proteins and genome RNA are assembled into virions and"/>
  <result pre="via vesicles and released out of the cell. ERGIC (ERâ€&quot;Golgi" exact="intermediate" post="compartment). Site of action for each therapeutic candidate is"/>
  <result pre="cross. ijms-21-05559-t001_Table 1Table 1 List of available drugs targeting SARS-CoV-2" exact="infection" post="and their effective dosage. Name of Medicine Target Classification"/>
  <result pre="Medicine Target Classification Effective Dosage Registered Clinical Trial Reference Remdesivir" exact="Viral" post="RNA polymerase Anti-viral IV injection 200 mg at day"/>
  <result pre="for 9 days NCT04257656, NCT04252664, NCT04292730, NCT04315948, NCT04321616 [237] Lopinavir/Ritonavir" exact="Viral" post="protease Anti-viral Oral administration 400 mg lopinavir and 100"/>
  <result pre="NCT04321174, NCT04350684, ISRCTN50189673, NCT04315948, NCT04328012, NCT04276688, ISRCTN50189673, NCT04321993 [114] Favipiravir" exact="Viral" post="RdRP Anti-viral Oral administration 1600 mg twice daily on"/>
  <result pre="day on day 2âˆ’14. 2020-001435-27, NCT04359615, NCT04303299, NCT04402203 [120] Ribavirin" exact="viral" post="RNA Anti-viral 500 mg each time, 2 to 3"/>
  <result pre="combination with IFN-Î± or lopinavir/ritonavir NCT04276688, NCT04392427, ChiCTR2000029387 [238] Arbidol" exact="Viral" post="RNA polymerase Anti-viral 200 mg three times a day"/>
 </snippets>
</snippetsTree>
